

Saskatchewan Cancer Control Report

Profiling Cancer Stage at Diagnosis



Saskatchewan Cancer Control Report Profiling Cancer Stage at Diagnosis

Recommended citation:

Alvi R, Zhu T, Narasimhan G, Tonita J. Saskatchewan Cancer Control Report Profiling Cancer Stage at Diagnosis. Saskatoon: Saskatchewan Cancer Agency; 2011.

Foreword

The Saskatchewan Cancer Agency is pleased to provide its latest edition of our Cancer Control Report. The purpose of this report is to inform the public, health providers and other organizations on the status of cancer control aspects in Saskatchewan. The focus of this year's report is on cancer staging.

The stage of a cancer is a description (usually numbers I to IV) of the extent the cancer has spread. Staging systems for cancer have evolved over time and continue to change as scientists learn more about cancer, but it is a very important aspect of every patient's journey. Before any treatment starts, three essential factors should be known: the site of origin, the histological type (including grade) and the extent or stage of the cancer. Cancer staging is an important component, not only of patient care, but also of research and cancer control:

- As a key indicator for the success of early detection programs where the focus is on finding cancers at an early stage to improve outcomes for the population.
- To help develop programs for specific types of cancer to assist in controlling the disease through detection and screening, prevention and treatment, or through a combination of all three mechanisms.
- By oncologists to plan the appropriate treatment.
- To estimate a patient's prognosis.
- To identify clinical trials that may be suitable for a particular patient.
- By healthcare providers and researchers to exchange information about patients. It also gives them a common terminology for evaluating the results of clinical trials and comparing the results of different trials.

As the provincial organization responsible for providing cancer prevention, screening, treatment and research, the Saskatchewan Cancer Agency uses cancer staging as an important tool in treating patients and finding ways to develop programs best suited to different stages of the disease.

This is the first time the Cancer Agency has published staging data, and we hope this report will increase your understanding of how cancer staging informs our work, particularly for the four most diagnosed forms of the disease.

I want to extend my thanks to our epidemiology staff, including Riaz Alvi, Tong Zhu and Dr. Jon Tonita, for their work in preparing this report.



Scott Livingstone
Chief Executive Officer



Table of Contents

| | Page |
|---|------|
| Key Findings | 3 |
| Introduction..... | 4 |
| Cancer Trends in Saskatchewan | 5 |
| Cancer Staging | 8 |
| Results..... | 10 |
| Glossary of Terms..... | 17 |
| Methods | 17 |
| References | 18 |
| Appendix A - Anatomical Diagram..... | 19 |
| Appendix B - Categories and Labels | 20 |
| Appendix C - 2005-2007 Statistical Tables | 21 |

Key Findings

- The number of new cancers in females increased 37 per cent from 1988 to 2007, while the overall age-adjusted incidence rate increased only 16 per cent.
- The number of new cancers in males increased 24 per cent from 1988 to 2007, a smaller increase than seen in females, while the overall age-adjusted incidence rate increased only 10 per cent.
- Colorectal cancer stage information in this report serves as a valuable baseline measure as the Saskatchewan Cancer Agency implements the Screening Program for Colorectal Cancer. More than half of the cases diagnosed from 2005 to 2007 were at an advanced stage at diagnosis.
- Small cell lung cancer stage distribution is much worse than non-small cell lung cancer. Overall, more than 80 per cent of cases were at an advanced stage at diagnosis.
- Breast cancer stage distribution is better for women screened through the Agency's Screening Program for Breast Cancer in comparison to those outside the program.
- Prostate cancer stage distribution gets slightly worse with age. Seventy-six percent were at a localized stage at diagnosis.
- Fifty per cent of deaths in women under 75 years of age in 2007 were caused by lung, breast or colorectal cancer, all sites where preventive measures or screening could have significant impact.
- Forty-one per cent of deaths in men under 75 years of age in 2007 were caused by lung or colorectal cancer, all sites where preventive measures or screening could have significant impact.



Introduction


This is the fourth edition of the Saskatchewan Cancer Control Report, providing a description of the burden of cancer in Saskatchewan. As in previous editions, we have provided a 20-year view on cancer incidence and mortality, covering the years 1988 to 2007. Trends of our most common cancers are provided, as well as the detailed annual tables of incidence and mortality by cancer type and age group for the years 2005, 2006 and 2007.

The special topic for this report is on cancer stage. Stage is a measure of the extent of disease at the time of diagnosis. The most common categories for stage include localized, regional and distant. Local stage cancers are still confined to the original tissue of origin. In others words there is no sign of disease spread beyond the initial site. Regional stage are cancers that have spread to nearby tissues or structures from the initial site, and distant stage cancers have spread to other parts of the body.

The staging system used by the Saskatchewan cancer registry is known as the Collaborative Staging (CS) system managed by the American Joint Committee on Cancer. The CS is widely adopted throughout North America as the common cancer staging system for registries. The data in this report uses version 1 of the CS. In future, version 2 will be incorporated into the provincial registry, starting with 2010 data.

Stage at diagnosis is one of the most important pieces of information for any cancer diagnosed. The information is used by physicians to establish the treatment plan required and is a key prognostic factor for patient outcomes. For many cancers diagnosed with localized stage, five-year survival rates are in excess of 90 per cent, whereas cancers diagnosed with distant stage could have five-year survival rates less than 10 per cent. Knowledge of the stage distribution for some cancers in the population is also very important for monitoring progress in our cancer early detection programs. These programs aim to diagnose cancers with more favourable staging leading to reduced cancer mortality and morbidity.

In this report we have provided stage information for the top four cancers in Saskatchewan: lung, prostate, breast, and colorectal. Each has very different stage distributions and together, these sites reflect our challenges, opportunities and successes in cancer control. Lung cancer remains a challenge because most cases are diagnosed in advanced stage, even though most are avoidable with preventive measures. Prostate cancers are mostly diagnosed in localized stage but there remains significant debate about the usefulness of early detection for this disease. With breast cancer, we see the impact of our provincial Screening Program for Breast Cancer, comparing the stage of women diagnosed through the program versus those who did not attend the program. Finally, for colorectal cancer we have established a pre-screening program baseline to evaluate our new Screening Program for Colorectal Cancer. As with breast cancer, the goal is to diagnose more localized colorectal cancer cases resulting in improved patient outcomes.



Cancer Trends in Saskatchewan

Incidence and Mortality

Figure 1 shows the annual number of new invasive cancers diagnosed and the age-adjusted rates since 1988. In 1988 there were 2,099 cases diagnosed in males and 1,725 in females. By 2007, this had increased to 2,610 and 2,367, respectively.

The average annual percent increase among women is about 1.6 times higher than in men (1.9% vs. 1.2%), which can be attributed to the large increase in the number of lung cancers diagnosed in females over this time period (shown later). In males, a peak in the total number of cases occurred in 2004. This is mainly due to the increase in prostate cancer cases diagnosed that year.

Figure 1 also shows that age-adjusted incidence rates increased from 1988 to 2007. Adjusted rates control for changes in age distribution over time (see Glossary). Compared to increases in the number of cases diagnosed, the increase in rates has been more modest. In females, the number of cases increased by 37%, while the rates increased by 16%; in males, the number of cases increased by 24% but the rates only increased by approximately 10%. This difference is due to the aging of the population over time. Cancer is most common in people over 50, and this subgroup of the population grew during the 20-year period from 1988 to 2007.

Figure 2 shows the number of cancer deaths and age-adjusted mortality rates by sex for the province. The number of deaths among men stayed fairly stable over the 20-year period. In 2007, 1,180 men died from cancer, compared to 1,175 in 1988. The age-adjusted mortality rates for males have followed a downward trend since 2002. The picture is different for women: cancer deaths increased by about 23% from 851 deaths in 1988 to 1,045 in 2007. Detailed tables for incidence and mortality counts and rates for the years 2005, 2006 and 2007, organized by cancer site and age group, are provided in Appendix C.

Figure 1: Number of Invasive Cancers and Age-Adjusted Incidence Rates, 1988-2007





Figure 2: Number of Deaths from Cancer and Age-Adjusted Mortality Rates, 1988-2007



Cancer Trends in Saskatchewan

Incidence Rates of Common Cancers

Between 1988 and 2007, there were markedly different trends in incidence of the three most common cancers in men – prostate, colorectal and lung (Figure 3). Incidence of prostate cancer, which is the most commonly diagnosed, changed dramatically, largely due to the introduction of prostate specific antigen (PSA) testing in Saskatchewan in 1990. After peaking in 1993, age-adjusted incidence rates dropped to previous levels before rising again sharply starting in 1997. The widespread and unorganized nature of PSA testing in Saskatchewan may be influencing the lack of stability in the age-adjusted rate¹.

Lung cancer rates in men have decreased gradually over time. The age-adjusted rate was highest in 1990, at 79 per 100,000, but fell to 59 per 100,000 by 2007. Incidence of colorectal cancer was more or less stable over this time period.

Figure 4 shows the trend in age-adjusted incidence rates for other common cancers in men. The 45% drop in stomach cancer rates over the 20-year period continues a trend that began in the 1950s. Bladder cancer rates declined slowly after peaking in the early 1990s. The sharp drop in rates seen in 2002 was due to a change in ICD-O coding, which reduced the number of invasive cases recorded. While rates of melanoma were relatively stable over the time period, rates of non-Hodgkin's lymphoma increased from 14 per 100,000 in 1990 to 21 per 100,000 in 2007.

Figure 5 shows the incidence trend for the three most common cancers among women. In 1988 the age-adjusted rate of breast cancer was 93 per 100,000; by 1990 this rate had increased about 17%, to 109 per 100,000. After 1990 breast cancer rates remained stable, fluctuating between 100 and 110 per 100,000. Rates of lung cancer, however, increased substantially. The age-adjusted rate increased 71% over 20 years, from 27 per 100,000 to 46 per 100,000. By 2006 the rate for lung cancer was slightly higher than that for colorectal cancer, which was relatively stable over time.

Figure 3: Age-Adjusted Incidence Rates for Common Invasive Cancers in Males, 1988-2007




Figure 4: Age-Adjusted Incidence Rates for Selected Invasive Cancers in Males, 1988-2007





Figure 5: Age-Adjusted Incidence Rates for Common Invasive Cancers in Females, 1988-2007



Cancer Trends in Saskatchewan

Figure 6 shows trends in age-adjusted rates for common cancers among women. Uterine cancer rates fluctuated between 18 per 100,000 and 23 per 100,000 over the 20-year period. Rates of non-Hodgkin's lymphoma rose in a pattern similar to that seen in men, from a low of 11 per 100,000 in 1988 to as high as 17 per 100,000 in 1994 and, more recently, 16 per 100,000 in 2006. Melanoma rates hovered around 10 per 100,000 from 1988 to 2007. Although the rate of stomach cancers remained around six per 100,000 for most of the period, it fell after 2000 before gradually rising to five per 100,000 in 2007.

Mortality Rates of Common Cancers

Figure 7 shows the age-adjusted mortality rates for common cancers in women. The largest increase was in lung cancer deaths, which rose from 24 per 100,000 in 1988 to 35 per 100,000 in 2007. Breast cancer mortality rose to as high as 32 per 100,000 in 1990, but has followed a downward trend since then, with a 37% reduction to 20 per 100,000 in 2007. Colorectal cancer mortality also dropped during this period, from 17 per 100,000 in 1988 to 14 per 100,000 in 2007.

Figure 8 shows the age-adjusted mortality rates for common cancers in men. Rates for lung cancer, the most common cancer cause of death, began declining in 1996. Lung cancer mortality rates have been decreasing consistently since 1999, with a reduction of 23% to 47 per 100,000 in 2007. Colorectal cancer mortality was fairly stable in men as compared to the decline in rates seen among women. Rates of prostate cancer mortality peaked at about 37 per 100,000 in 1999-2000, but have since decreased 24% to 28 per 100,000 in 2007.

Figure 6: Age-Adjusted Incidence Rates for Selected Invasive Cancers in Females, 1988-2007




Figure 7: Age-Adjusted Mortality Rates for Common Invasive Cancers in Females, 1988-2007





Figure 8: Age-Adjusted Mortality Rates for Common Invasive Cancers in Males, 1988-2007



Cancer Staging

How Is Cancer Staged?

Staging is the process of determining how much cancer there is in the body and where it is located. The stage describes the extent or spread of the disease at the time of diagnosis and is essential in determining the appropriate therapy and prognosis. A cancer's stage is based on the size and location of the primary tumour, as well as whether it has spread to other areas of the body. A number of different staging systems are used to classify tumours.

The TNM staging system assesses three factors: extent of the primary tumour (T), absence or presence of regional lymph node involvement (N), and absence or presence of distant metastases (M). Once the T, N and M are determined, a stage of 0, I, II, III, or IV is assigned based upon the findings. Stages 0 and I represent early stage and stage IV corresponds to advanced disease (see diagram this page).

In the Collaborative Stage (CS) system, T, N and M data, along with selected non-anatomic factors, are analyzed using a computer-based algorithm. The algorithm produces a TNM stage as defined in the American Joint Committee on Cancer (AJCC) Cancer Staging Manual². An advantage of the CS system is that it provides standardized rules for timing, clinical and pathologic assessments, and compatibility of descriptions for all cancer sites. By inputting information into CS it is possible to derive the corresponding stage in a variety of the main staging systems.


Surveillance Epidemiology and End Results (SEER) summary staging, which classifies cancers as *in situ*, local, regional, and distant, is used for descriptive and statistical analysis of tumour registry data. *In situ* indicates the presence of malignant cells within the cell group from which they arose, without any spread to other areas. *Localized* refers to a malignancy that has spread no further than the organ of origin. A *regional* stage indicates that the tumour extends beyond the limits of the organ of origin. *Distant* metastases are tumour cells that have broken away from the primary tumour, travelled to other parts of the body, and begun to grow at the new location.^{3,4} Summary staging does not include detailed information; however, it is broad enough to measure the success of cancer control and other epidemiologic efforts.

How is it Staging Used?

In addition to describing the extent or severity of an individual's cancer, staging also helps clinicians plan a patient's treatment, estimate a patient's prognosis, and identify appropriate clinical trials. Cancer staging also provides a common reference point for researchers comparing studies and evaluating the results of clinical trials.⁵

History of Cancer Staging

The practice of staging cancer started over a hundred years ago. Initially, efforts were focused on cancers with specific anatomic sites. French surgeon Pierre Denoix's tumour-node-metastasis (TNM) classification, which he developed between 1943 and 1952, was the first staging system with principles and codes that could be applied to all cancer sites.⁶ In 1958, the first international TNM recommendations were published by the Union for International Cancer Control (UICC) for the clinical stage classification of cancers of the breast and larynx.⁷ Between 1960 and 1967, nine UICC brochures were published describing proposals for the classification of tumours at 23 body sites. In 1968, these brochures were combined, representing the *First Edition* of TNM.⁸ In 1974 and 1978, the *Second* and *Third Editions*^{9,10} were published, containing new site classifications and amendments to previously published classifications. The *Third Edition* was enlarged and revised in 1982.



Example of Staging for Colorectal Cancer

Cancer Staging

Over the years, variations in the rules of classification for certain sites were introduced. In order to achieve standardization, in 1982 the national TNM committees agreed to formulate a single TNM classification. A series of meetings was held to unify and update existing classifications, as well as to develop new ones. The result was the *Fourth Edition* of TNM, coordinated with the UICC and AJCC and representing the achievement of a worldwide agreement for the staging of adult solid tumours.¹¹ Each subsequent edition of the TNM classification was accompanied by an illustrated *TNM Atlas*,^{12,13} which graphically depicts the T and N categories.

In 1993, the UICC's TNM project published the *TNM Supplement*.¹⁴ Its purpose was to promote the uniform use of TNM by providing detailed explanations of the TNM rules with practical examples. It also included proposals for new classifications and optional expansions of selected categories. In 1995, the project published *Prognostic Factors in Cancer*,¹⁵ a compilation and discussion of prognostic factors in cancer at each of the body sites. This was updated in 2002 and 2006 with *Second* and *Third Editions*.^{16,17}

Since the *Fourth Edition*, the TNM classifications used by the UICC and the AJCC have been identical, owing to the close cooperation and communication between these two bodies. Thus, the present (*Sixth*) UICC edition of TNM¹⁷ contains rules of classification and staging that correspond exactly with those of the *Sixth Edition* of the *AJCC Cancer Staging Manual*.¹⁹ TNM now appears in over a dozen translations and is available online.²⁰

To date, there have been six editions of both the UICC and AJCC publications. A *Seventh Edition* was published in the spring of 2009. The development of these staging strategies relies upon the latest data and research published in peer-reviewed journals.

Cancer Staging at the Saskatchewan Cancer Registry

Cancer stage information for selected cancer sites has been collected at the Saskatchewan cancer registry (SCR) since 1970. In 2005 the SCR began collecting Collaborative Stage Version 1 for colorectal and breast cancers. Lung cancers were staged using this system beginning in 2006 and prostate in 2007. The SCR will stage all new cases for all cancer sites from 2010 forward using Collaborative Stage. Stage distribution for these sites using the SEER summary stage are presented in the results section.



Results

Colorectal Cancer

Collaborative Staging and SEER Summary Staging for colorectal cancer by the Saskatchewan cancer registry (SCR) began in 2005. Colorectal cancer staging information reported from 2005 to 2007 is included in this report. There were 2,174 colorectal cancer cases over the three years.

The distribution of colorectal cancer stages is shown in Figure 9. The majority of cases (53%) were regional or distant. In situ and localized cases represented 41% of the total. The remaining cases were not staged.

Figure 9: Colorectal Cancer Stage Distribution, 2005-2007




Figure 10 shows the age distribution of colorectal cancer stages. Among all age groups, localized cases made up the largest proportion, followed by regional and distant cases. It is interesting to note that individuals age 70 and older had the highest proportion of localized cases and lowest proportion of distant cases compared to the other age groups. This may be due to increased screening of older as compared to younger people. This distribution is similar to the SEER registries in the United States.²¹

Figure 10: Colorectal Cancer Stage Distribution by Age Group, 2005-2007




Figure 11 shows a comparison of the distribution of age-standardized rates of colorectal cancer stages for males and females. While the relative distribution was similar for both sexes, the rate was highest for localized cases, followed by regional and distant cases. For both sexes, there were much lower rates of in situ cases and cases that were not staged. It is notable that the overall rates were much higher for males than for females for localized, regional and distant cases.

Figure 11: Age-Adjusted Incidence Rates for Colorectal Cancer by Stage and Sex, 2005-2007





Figure 12 shows the distribution of colorectal cancer grouped by sub-site. Examining the sub-site distribution can help evaluate screening and treatment methods. For detailed anatomical information on the various sub-sites, see Appendix A. *Colon* refers to colon cancers where it was either not possible to determine the point of origin or it was not specified. The majority (86%) of colorectal cancer cases involved the right colon, sigmoid and rectosigmoid colon, and rectum and anus. The other sub-sites together make up only 14% of cases.


Figure 12: Colorectal Cancer Distribution by Sub-site, 2005-2007



Results

Figure 13 shows the distribution of colorectal cancer by sub-site and sex. Right colon, sigmoid and rectosigmoid, and rectum and anal cancers made up the highest proportion of cases among both sexes. However, females had a higher proportion of right colon, transverse colon and non-specified cancers as compared to males, while males had higher proportions of splenic and descending, sigmoid and rectosigmoid, and rectum and anal cancer than females.

Figure 13: Colorectal Cancer Distribution by Sub-site and Sex, 2005-2007



The distribution of stages for cases of right colon cancer is shown in Figure 14. The highest proportion of cases diagnosed was regional, followed by localized and distant. Regional and distant stages together comprised 61% of cases. In situ cases and localized were 35% and cases that were not staged made up the remaining 4%.

Figure 14: Right Colon Cancer Stage Distribution, 2005-2007






Figure 15 shows the distribution of stages for cases of transverse colon cancer. Half of the cases (51%) were regional or distant, followed by localized cases, cases that were not staged, and in situ cases.

Figure 15: Transverse Colon Cancer Stage Distribution, 2005-2007



The distribution of stages for cases of splenic and descending colon cancer is shown in Figure 16. The majority of cases (54%) were either regional or distant, followed by localized cases (37%). Cases that were not staged and in situ cases made up the remaining 9%.

Figure 16: Splenic and Descending Colon Cancer Stage Distribution, 2005-2007



Results

The distribution of stages for cases of colon cancer is shown in Figure 17. The majority of cases (65%) were regional or distant at the time of diagnosis, followed by cases that were not staged and localized. In situ cases made up only 3% of total cases.

Figure 17: Colon Cancer Stage Distribution, 2005-2007




Figure 18 shows the distribution of stages for cases of sigmoid and rectosigmoid cancer. Localized or in situ cases made up about half (48%), with the other half distant or regional (49%). The remaining 3% of cases were classified as not staged.

Figure 18: Sigmoid and Rectosigmoid Cancer Stage Distribution, 2005-2007





Figure 19 shows the distribution of stages for cases of rectal and anal cancer. The majority of cases (47%) were localized or in situ, followed by regional or distant cases, and cases that were not staged.

Figure 19: Rectal and Anal Cancer Stage Distribution, 2005-2007




All of the detailed colorectal cancer stage distribution information presented serves as a baseline measure as the Saskatchewan Cancer Agency implements the Screening Program for Colorectal Cancer.

Lung Cancer

Collaborative Staging and SEER Summary Staging for lung cancer by the SCR began in 2006. Lung cancer staging information reported from 2006 to 2007 is included in this report. There were 1,363 lung cancer cases over the two years.

Figure 20 shows the distribution of stages for lung cancer cases in both sexes. The majority of cases (84%) were regional or distant at the time of diagnosis. The remaining 13% of cases were localized, and a small proportion of cases were not staged. There were no in situ cases diagnosed from 2006-2007.

Figure 20: Lung Cancer Stage Distribution, 2006-2007



Results

The age distribution of lung cancer stages is shown in Figure 21. Relative proportions of each stage were similar across the age groups. The youngest age group, however, had the highest proportion of distant cases and the lowest proportion of localized cases diagnosed.

Figure 21: Lung Cancer Stage Distribution by Age Group, 2006-2007




Figure 22 shows a comparison of the distribution of age-standardized rates of lung cancer for males and females. While the relative distribution was similar for both sexes, the overall rate of distant cases was significantly higher for males as compared to females. The rate of regional cases was slightly higher in males and the rate of localized cases was slightly higher in females.

Figure 22: Age-Adjusted Incidence Rates for Lung Cancer by Stage and Sex, 2006-2007






Figure 23 shows the distribution of lung cancer grouped by type. The vast majority of lung cancer cases diagnosed were non-small cell cancers. There are two major types of lung cancer: non-small cell and small cell. Each grows and spreads in different ways and is treated differently. Small cell lung cancer grows quickly and often spreads to distant parts of the body. Small cell lung cancer is much less common than non-small cell; however, the survival for small cell is poor in comparison to non-small cell.^{22,23}

Figure 23: Lung Cancer Distribution by Type, 2006-2007




Figures 24 and 25 show the distribution of stages for cases of small cell and non-small cell lung cancer. The majority of cases were distant at the time of diagnosis for both small cell and non-small cell lung cancer. Small cell lung cancer was more aggressive in comparison to non-small cell lung cancer, however, as evidenced by its relatively higher proportion of distant cases and significantly lower proportion of localized cases.

Figure 24: Small Cell Lung Cancer Stage Distribution, 2006-2007




Results

Figure 25: Non-Small Cell Lung Cancer Stage Distribution, 2006-2007



Age-standardized incidence rates for small cell and non-small cell lung cancer cases are shown in Figure 26. Rates of non-small cell cancer were significantly higher than rates of small cell cancer among both males and females. The rate of non-small cell cancer was higher in males compared to females and the rate of small cell cancer was higher in females compared to males.

Figure 26: Age-Adjusted Incidence Rates for Lung Cancer by Type and Sex, 2006-2007



Figures 27 and 28 show age-standardized incidence rates of lung cancer by type and stage for both sexes. The distribution of cases by type and stage was similar for both sexes. In both sexes, distant cases made up the highest proportion of both small cell and non-small cell cancers. In both males and females, small cell cancers had higher proportions of distant cases than non-small cell cancers. Males had a higher proportion of distant cancers among both small cell and non-small cell cancers.

Figure 27: Lung Cancer Stage Distribution by Type in Females, 2006-2007





Figure 28: Lung Cancer Stage Distribution by Type in Males, 2006-2007




Results

Breast Cancer

Collaborative Staging and SEER Summary Staging for breast cancer by the SCR began in 2005. Breast cancer staging information reported from 2005 to 2007 is included in this report. There were 2,291 breast cancer cases in females over the three years.

Figure 29 shows the distribution of stages for breast cancer cases. Sixty-two percent of cases were localized or in situ at the time of diagnosis. The majority of the remaining cases were regional (32%), and distant and cases that were not staged made up a smaller proportion of cases (6%).

Figure 29: Breast Cancer Stage Distribution, 2005-2007



The age distribution of breast cancer stages is shown in Figure 30. In the two older age groups, localized cases made up the largest proportion, followed by regional, in situ, and then distant cases. In the younger age group, regional cases made up a slightly higher proportion than localized cases, followed by in situ and distant cases. It is also notable that the age 70+ group had the highest proportion of distant cases, relative to the other two age groups.

Figure 30: Breast Cancer Stage Distribution by Age Group, 2005-2007






Figure 31 shows age-standardized rates of breast cancer among females from 2005-2007. The rate of localized cases was about three times higher than rates of in situ, distant and unknown cases combined. The rate of regional cases was second highest at about double the rates of in situ, distant and unknown cases combined.

Figure 31: Age-Adjusted Incidence Rates for Breast Cancer by Stage, 2005-2007



The distribution of stages for cases of breast cancer among women screened at the Screening Program for Breast Cancer (SPBC) compared to the distribution for cases among women who did not attend SPBC is shown in Figure 32. Note that the target population for breast cancer screening in Saskatchewan is women 50-69 years of age.

Figure 32: Breast Cancer Distribution by Screening Status and Stage, 2005-2007



Results

Women who were screened at SPBC had a higher proportion of in situ and localized cases compared to women who were not. A very small proportion of cases screened at SBPC were distant or not staged. Women not screened at SPBC had a higher proportion of regional and distant cases and cases that were not staged, compared to women who did attend SPBC.


A similar trend is seen in Figure 30, where the proportion of cases staged as in situ and localized in the 50-69 age group were more than the 0-49 age group. This suggests that screening results in female breast cancer being caught at an earlier stage. Cancer detected at an earlier stage as a result of screening can result in a less invasive treatment and greater life expectancy.

Prostate Cancer

Collaborative Staging and SEER Summary Staging for prostate cancer by the SCR began in 2007. The 878 cases diagnosed that year are included in this report.


Figure 33 shows the distribution of stages for cases of prostate cancer. The majority of cases were localized at the time of diagnosis. Regional and distant cases together made up about 20% of cases, while in situ cases and cases that were not staged made up a very small proportion of the total.

Figure 33: Prostate Cancer Stage Distribution, 2007



The age distribution of stages for cases of prostate cancer is shown in Figure 34. Although localized cases made up the largest proportion among all age groups, this proportion decreased with increasing age. Regional cases made up the second highest proportion among those under 60. The proportion of distant cases and those that were not staged increased with increasing age.

Figure 34: Prostate Cancer Stage Distribution by Age Group, 2007



Glossary of Terms

Standardized Incidence Rate (Age-Adjusted Incidence Rate)

A statistical technique used to remove, as much as possible, the effects of differences in age when comparing two or more populations. An age-adjusted incidence rate represents the number of new cases of cancer that would have occurred if the age distribution of the study population during a particular time period was the same as the standard population (i.e. 1991 Canadian population).

Age-Specific

The number of cases of particular event in a given age group.

Behaviour

In cancer, a designation of whether the tumour is malignant, benign, in situ, or uncertain.

Covered Population

The covered population is based on eligibility for health insurance benefits in Saskatchewan. All residents of Saskatchewan are included except members of the Canadian Armed Forces, members of the Royal Canadian Mounted Police, inmates of federal prisons, and people not yet meeting the residency requirement.

Incidence

The number of new cases of a particular event.

Invasive Cancer

The uncontrolled growth of cells resulting in the formation of a malignant tumour that invades underlying tissues.

In Situ Cancer

Confined to the site of origin without invasion of neighboring tissue.

Metastases

Tumours formed by cells that have spread from one part of the body to another.

SEER (Surveillance Epidemiology and End Results)

Program of the National Cancer Institute that provides information on cancer incidence and survival in the United States.

Methods

The data for this report was provided by the Saskatchewan cancer registry (SCR), which is maintained by the Saskatchewan Cancer Agency. A detailed description of the history of the registry, its data sources, the coding classifications, and information recorded is provided in the first issue of the Saskatchewan Cancer Control Report.²⁴

All cases of invasive and in situ cancer were retrieved from the SCR. For each case, information including age at diagnosis, sex, date of diagnosis, tumour site, and morphology, stage and behavior at date of diagnosis was obtained.

The cancers were grouped into common site categories using the ICDO-T, ICDO-M and behaviour codes as indicated in Appendix B. These site categories were used for all analysis.


All age adjustments were done by the direct method using the 1991 Canadian population as the standard. Saskatchewan's covered population was used as the denominator to calculate rates.

References

1. Tonita JM, Skarsgard D, & Muhajarine N. Changes in cases mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era. *Cancer Causes Control* 2009;20:201-209.
2. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, and Trotti A (editor) American Joint Committee on Cancer AJCC Cancer Staging Manual Seventh Edition Springer 2010 page 5.
3. Cancer Facts and Figures 2008 Accessed on September 30, 2009 <http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf> Page 3.
4. Yong JL, Roffers SD, Ries LAG, Fritz AG, & Hurlbut AA. SEER summary staging manual-2000 codes and coding instructions. Accessed on February 25, 2010 <http://www.seer.cancer.gov/tools/ssm/intro.pdf>
5. National Cancer Institute, Cancer staging. Accessed on February 26, 2010. <http://www.cancer.gov/cancertopics/factsheet/Detection/staging>
6. Greene FL, Sobin LH. The Staging of Cancer: A Retrospective and Prospective Appraisal. *CA Cancer Journal for Clinicians* 2008;58: 180-189. Denoix PF. Nomenclature classification des cancer [in French]. *Bull Inst Nat Hyg (Paris)* 1952;7:743-748.
7. UICC Committee on Clinical Stage Classification and Applied Statistics. Clinical Stage Classification and Presentation of Results. Malignant Tumours of the Breast and Larynx. Paris, France: Union for International Cancer Control; 1958.
8. Union for International Cancer Control. TNM Classification of Malignant Tumours. Geneva, Switzerland: Union for International Cancer Control; 1968.
9. Union for International Cancer Control. TNM Classification of Malignant Tumours. 2nd ed. Geneva, Switzerland: Union for International Cancer Control; 1974.
10. Harmer MH, ed. TNM Classification of Malignant Tumours. 3rd ed. Geneva, Switzerland: Union for International Cancer Control; 1978. Enlarged and revised 1982.
11. Hutter RV. At last-worldwide agreement on the staging of cancer. *Arch Surg* 1987;122:1235-1239.
12. Wittekind C, Greene FL, Hutter RV, et al. TNM Atlas: Illustrated Guide to the TNM Classification of Malignant Tumours. 5th ed. Hoboken, NJ: John Wiley & Sons; 2005.
13. Greene FL Compton CC, Fritz AG, et al. AJCC Cancer Staging Atlas. New Yourk, NY: Springer, Inc.;2006.
14. Hermanek P, Henson DE, Hutter RV, Sobin LH. International Union Against Cancer (UICC): TNM Supplement 1993. A Comentary on Uniform Use. New York, NY: Springer-Verlag; 1993.
15. Hermanek P, Gospodarowicz MK, Henson DE, et al. International Union Against Cancer (UICC): Prognostic Factors in Cancer. New York, NY: Springer-Verlag; 1995.
16. Gospodarowicz MK, Henson DE, Hutter RV, et al. Prognostic Factors in Cancer. 2nd ed. New York, NY: Wiley-Liss; 2001.
17. Gospodarowicz MK, O'Sullivan B, Sobin LH. Prognostic Factors in Cancer. 3rd ed. New York, NY: Wiley; 2006.
18. Sobin LH, Wittekind C. International Union Against Cancer (UICC) TNM Classification Of Malignant Tumours. 6th ed. New York, NY: Springer; 2002.
19. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
20. TNM Online. Available at: <http://www3.interscience.wiley.com/cgi-bin/mrwhome/104554799/HOME>. Accessed on October 8, 2009.
21. Surveillance Epidemiology and End of Results (SEER) cancer statistics National Cancer Institute <http://seer.cancer.gov/faststats/selections.php?#Output> Accessed on November 24, 2010.
22. American Cancer Society. Learn about cancers. <http://www.cancer.org/Cancer/index> Accessed on November 24, 2010.
23. Canadian Cancer Society. What is lung cancer. <http://www.cancer.ca/Canada-wide/About%20cancer/Types%20of%20cancer/What%20is%20lung%20cancer.aspx> Accessed on November 24, 2010.
24. Tonita J, Alvi R, Wastson F, Robson D. Saskatchewan Cancer Control Report: Profiling Trends in Cancer, 1970-2001. Regina: Saskatchewan Cancer Agency; 2003.

Appendix A

The right colon includes the cecum, appendix, ascending colon, and hepatic flexure of the colon. Transverse colon represents an independent group. Splenic flexure and descending colon include the splenic flexure of the colon and the descending colon. *Colon* refers to colon cancers where it was either not possible to determine the point of origin or it was not specified. It includes overlapping lesion of colon and colon, NOS (not otherwise stated). Sigmoid and rectosigmoid include the sigmoid colon and rectosigmoid junction. Rectum and anal includes the rectum, anus, anal canal, and overlapping lesion of rectum, anus, and anal canal.



Appendix B

ANNUAL REPORT CATEGORIES AND LABELS

| Site | ICDO-T (Topography) | ICDO-M (Morphology) | Behaviour |
|--|---|------------------------|-----------|
| Lip | C000-C009 | | 3 |
| Oral Cavity | C019-C069 | | 3 |
| Head and Neck | C079-C148 | | 3 |
| Esophagus | C150-C159 | | 3 |
| Stomach | C160-C169 | | 3 |
| Small Intestine | C170-C179 | | 3 |
| Colon | C180-C189 | | 3 |
| Rectum | C199-C218 | | 3 |
| Liver | C220 | | 3 |
| Gallbladder and Biliary Tract | C221-C249 | | 3 |
| Pancreas | C250-C259 | | 3 |
| Digestive Tract | C260-C269 | | 3 |
| Respiratory System | C300-C319, C379, C380-C399 | | 3 |
| Larynx | C320-C329 | | 3 |
| Trachea, Bronchus and Lung | C339-C349 | | 3 |
| Bone and Connective tissue | C400-C419, C490-C499 | | 3 |
| Malignant Melanoma | C440-C449 | 8720-8790 | 3 |
| Skin | C440-C449 | Not 8720-8790 | 3 |
| Breast | C500-C509 | | 3 |
| Female Genital Organs | C510-C519, C529, C570-C589 | | 3 |
| Cervix | C530-C539 | | 3 |
| Uterus | C540-C559 | | 3 |
| Ovary | C569 | | 3 |
| Male Genital Organs | C600-609, C620-C639 | | 3 |
| Prostate | C619 | | 3 |
| Kidney | C649 | | 3 |
| Other Urinary Tract | C659, C669, C680-C689 | | 3 |
| Bladder | C670-C679 | | 3 |
| Brain and Central Nervous System | C700-C709, C710-C729 | | 3 |
| Thyroid | C739 | | 3 |
| Other Endocrine Glands | C740-C759 | | 3 |
| Non-Hodgkin's Lymphoma | | 9670-9729; 9590-9596 | 3 |
| Hodgkin's lymphoma | | 9650-9667 | 3 |
| Multiple Myeloma | | 9730-9739 | 3 |
| Leukemia | | 9800-9949 | 3 |
| Other Primaries | C470-C488, C690-C699, C760-C779, any other | | 3 |
| Other Primaries Hematologic/ Myeloproliferative etc | | 9950-9989 9740-9769 | 3 |
| Primary Unknown | C809 | | 3 |
| Cervix in situ | C53 | | 2 |
| Other in situ | Not C53 | | 2 |

Appendix C

INCIDENCE - AGE SPECIFIC NUMBERS (FEMALE) - 2005

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|----------|----------|-----------|-----------|-----------|-----------|------------|------------|------------|------------|------------|------------|------------|------------|-------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 2 | 3 | 1 | 2 | 3 | 15 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 0 | 8 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 4 | 8 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 2 | 1 | 0 | 1 | 3 | 3 | 11 | 25 |
| Colon | 0 | 0 | 1 | 1 | 2 | 1 | 1 | 4 | 6 | 14 | 22 | 30 | 22 | 33 | 79 | 216 |
| Rectum | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 9 | 8 | 5 | 2 | 8 | 10 | 13 | 22 | 81 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 4 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 4 | 2 | 2 | 8 | 6 | 27 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 7 | 3 | 11 | 8 | 6 | 11 | 28 | 76 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 3 | 9 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 5 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 10 | 13 | 28 | 53 | 47 | 38 | 38 | 68 | 301 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 2 | 2 | 1 | 9 |
| Bone and Connective Tissue | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 3 | 1 | 3 | 13 |
| Malignant Melanoma of Skin | 0 | 1 | 0 | 1 | 1 | 1 | 6 | 10 | 7 | 4 | 1 | 3 | 3 | 8 | 11 | 57 |
| Breast | 0 | 0 | 0 | 4 | 1 | 15 | 37 | 52 | 77 | 64 | 70 | 81 | 83 | 75 | 100 | 659 |
| Cervix: Invasive | 0 | 0 | 0 | 4 | 3 | 3 | 5 | 9 | 3 | 1 | 3 | 1 | 1 | 2 | 2 | 37 |
| Uterus | 0 | 0 | 0 | 1 | 2 | 2 | 5 | 8 | 19 | 17 | 20 | 8 | 8 | 9 | 19 | 118 |
| Ovary | 0 | 0 | 0 | 1 | 1 | 3 | 5 | 4 | 7 | 7 | 6 | 4 | 9 | 7 | 18 | 72 |
| Female Genital Organs | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 4 | 1 | 2 | 2 | 0 | 8 | 21 |
| Kidney | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 6 | 4 | 2 | 5 | 6 | 8 | 39 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 2 | 2 | 5 | 12 | 26 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 6 | 12 |
| Brain & Central Nervous System | 4 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 4 | 6 | 31 |
| Thyroid | 0 | 2 | 2 | 3 | 5 | 5 | 8 | 8 | 7 | 7 | 2 | 2 | 3 | 6 | 3 | 63 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 2 | 1 | 2 | 4 | 4 | 7 | 5 | 10 | 4 | 9 | 11 | 13 | 25 | 97 |
| Hodgkin's Disease | 0 | 1 | 2 | 2 | 3 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 14 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 5 | 2 | 1 | 2 | 6 | 23 |
| Leukemia | 5 | 0 | 1 | 0 | 0 | 3 | 1 | 2 | 2 | 5 | 4 | 4 | 12 | 9 | 16 | 64 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 3 | 4 | 7 | 28 | 49 |
| Other Primaries | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 9 | 8 | 4 | 8 | 23 | 58 |
| Total | 12 | 6 | 8 | 21 | 20 | 44 | 87 | 132 | 184 | 195 | 238 | 240 | 242 | 284 | 526 | 2239 |
| Non-Melanoma Skin | 0 | 4 | 2 | 5 | 4 | 12 | 32 | 65 | 66 | 68 | 78 | 84 | 136 | 161 | 429 | 1146 |
| Cervix: In Situ | 0 | 9 | 44 | 54 | 36 | 20 | 14 | 12 | 3 | 0 | 0 | 3 | 0 | 1 | 1 | 197 |
| Other: In Situ | 0 | 0 | 1 | 2 | 3 | 1 | 11 | 18 | 30 | 24 | 36 | 30 | 38 | 40 | 94 | 328 |

INCIDENCE - AGE SPECIFIC NUMBERS (MALE) - 2005

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|----------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 0 | 6 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 4 | 4 | 7 | 4 | 3 | 4 | 32 |
| Head and Neck | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 8 | 2 | 0 | 4 | 3 | 3 | 5 | 28 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 2 | 5 | 6 | 10 | 32 |
| Stomach | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 4 | 3 | 7 | 6 | 9 | 8 | 13 | 53 |
| Colon | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 4 | 10 | 18 | 19 | 36 | 43 | 36 | 56 | 227 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 8 | 4 | 14 | 27 | 22 | 28 | 27 | 30 | 165 |
| Liver | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 3 | 0 | 3 | 2 | 3 | 2 | 17 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 4 | 3 | 6 | 17 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 3 | 7 | 3 | 12 | 13 | 13 | 57 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 4 | 9 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 4 | 9 | 2 | 2 | 23 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 8 | 11 | 14 | 40 | 56 | 82 | 77 | 84 | 373 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 4 | 1 | 2 | 2 | 13 |
| Bone and Connective Tissue | 1 | 2 | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 0 | 3 | 16 |
| Malignant Melanoma of Skin | 0 | 0 | 1 | 0 | 2 | 3 | 6 | 6 | 10 | 12 | 11 | 5 | 7 | 9 | 11 | 83 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 5 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 9 | 39 | 85 | 132 | 168 | 138 | 133 | 149 | 854 |
| Male Genital Organs | 0 | 1 | 6 | 3 | 2 | 3 | 4 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 2 | 25 |
| Kidney | 3 | 0 | 0 | 0 | 1 | 2 | 5 | 5 | 6 | 5 | 13 | 14 | 8 | 12 | 9 | 83 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 5 | 5 | 8 | 13 | 9 | 18 | 29 | 92 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 4 |
| Brain & Central Nervous System | 7 | 1 | 1 | 1 | 0 | 0 | 5 | 3 | 1 | 2 | 5 | 1 | 2 | 4 | 3 | 36 |
| Thyroid | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 1 | 2 | 2 | 1 | 0 | 1 | 1 | 12 |
| Other Endocrine Glands | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 5 |
| Lymphoma | 0 | 1 | 0 | 0 | 1 | 2 | 5 | 7 | 7 | 7 | 9 | 10 | 12 | 22 | 16 | 99 |
| Hodgkin's Disease | 0 | 3 | 3 | 1 | 2 | 0 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 14 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 5 | 10 | 4 | 5 | 3 | 5 | 36 |
| Leukemia | 5 | 3 | 1 | 1 | 2 | 0 | 5 | 2 | 4 | 6 | 7 | 12 | 13 | 14 | 19 | 94 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 1 | 5 | 8 | 10 | 9 | 19 | 58 |
| Other Primaries | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 3 | 3 | 8 | 11 | 13 | 16 | 23 | 81 |
| Total | 17 | 11 | 16 | 7 | 15 | 16 | 54 | 70 | 132 | 203 | 326 | 400 | 431 | 429 | 522 | 2649 |
| Non-Melanoma Skin | 0 | 2 | 0 | 7 | 6 | 7 | 24 | 47 | 95 | 104 | 127 | 173 | 177 | 260 | 499 | 1528 |
| Other: In Situ | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 7 | 7 | 22 | 22 | 27 | 26 | 58 | 77 | 252 |

INCIDENCE - AGE SPECIFIC NUMBERS (FEMALE) - 2006

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|----------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 5 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 2 | 4 | 1 | 1 | 3 | 2 | 4 | 7 | 27 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 3 | 1 | 2 | 2 | 11 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 2 | 1 | 5 | 15 |
| Stomach | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 0 | 4 | 9 | 5 | 10 | 34 |
| Colon | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 6 | 10 | 21 | 21 | 16 | 43 | 76 | 200 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 6 | 10 | 11 | 8 | 8 | 13 | 17 | 10 | 90 |
| Liver | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 2 | 2 | 9 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 4 | 4 | 2 | 2 | 10 | 25 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 5 | 7 | 6 | 7 | 9 | 21 | 58 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 4 | 10 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 2 | 5 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 6 | 16 | 28 | 42 | 71 | 44 | 51 | 76 | 341 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 2 | 7 |
| Bone and Connective Tissue | 4 | 1 | 0 | 3 | 2 | 0 | 0 | 0 | 3 | 3 | 1 | 1 | 0 | 1 | 0 | 19 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 1 | 0 | 3 | 4 | 6 | 4 | 7 | 2 | 4 | 6 | 3 | 7 | 47 |
| Breast | 0 | 0 | 1 | 1 | 13 | 9 | 31 | 53 | 71 | 90 | 87 | 74 | 76 | 62 | 109 | 677 |
| Cervix: Invasive | 0 | 0 | 0 | 1 | 6 | 5 | 4 | 6 | 5 | 1 | 1 | 1 | 1 | 1 | 3 | 35 |
| Uterus | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 6 | 14 | 21 | 13 | 19 | 13 | 16 | 15 | 120 |
| Ovary | 0 | 0 | 1 | 2 | 1 | 2 | 0 | 8 | 8 | 5 | 5 | 11 | 8 | 11 | 17 | 79 |
| Female Genital Organs | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 2 | 8 | 17 |
| Kidney | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 3 | 9 | 5 | 6 | 8 | 7 | 12 | 58 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 2 | 3 | 5 | 2 | 3 | 19 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 3 | 2 | 9 |
| Brain & Central Nervous System | 1 | 1 | 1 | 0 | 1 | 4 | 1 | 2 | 3 | 3 | 8 | 0 | 3 | 3 | 5 | 36 |
| Thyroid | 0 | 1 | 1 | 4 | 5 | 1 | 6 | 12 | 8 | 4 | 6 | 1 | 1 | 1 | 2 | 53 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Non-Hodgkin's Lymphoma | 1 | 0 | 0 | 0 | 4 | 1 | 4 | 4 | 6 | 6 | 9 | 12 | 17 | 17 | 28 | 109 |
| Hodgkin's Disease | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 2 | 0 | 1 | 0 | 13 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 3 | 3 | 6 | 2 | 7 | 25 |
| Leukemia | 3 | 3 | 0 | 0 | 2 | 1 | 2 | 3 | 5 | 7 | 5 | 6 | 12 | 8 | 18 | 75 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 3 | 1 | 6 | 6 | 6 | 4 | 30 | 60 |
| Other Primaries | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 3 | 3 | 4 | 4 | 6 | 6 | 17 | 48 |
| Total | 15 | 8 | 7 | 13 | 34 | 44 | 75 | 128 | 183 | 228 | 246 | 283 | 271 | 290 | 512 | 2337 |
| Non-Melanoma Skin | 1 | 2 | 3 | 6 | 8 | 10 | 31 | 57 | 63 | 77 | 59 | 97 | 123 | 147 | 450 | 1134 |
| Cervix: In Situ | 0 | 7 | 45 | 51 | 21 | 18 | 15 | 4 | 2 | 3 | 3 | 2 | 1 | 0 | 0 | 172 |
| Other: In Situ | 0 | 0 | 2 | 1 | 4 | 5 | 10 | 9 | 31 | 30 | 23 | 35 | 29 | 36 | 102 | 317 |

INCIDENCE - AGE SPECIFIC NUMBERS (MALE) - 2006

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|----------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 0 | 3 | 9 |
| Oral Cavity | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 5 | 7 | 4 | 5 | 1 | 1 | 0 | 27 |
| Head and Neck | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 5 | 5 | 3 | 4 | 4 | 2 | 29 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 3 | 2 | 0 | 7 | 4 | 9 | 30 |
| Stomach | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 6 | 14 | 3 | 9 | 11 | 51 |
| Colon | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 4 | 13 | 14 | 16 | 32 | 35 | 47 | 54 | 217 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 10 | 10 | 13 | 17 | 18 | 18 | 16 | 30 | 133 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 6 | 2 | 2 | 1 | 3 | 18 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 2 | 1 | 3 | 3 | 13 |
| Pancreas | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 3 | 7 | 6 | 4 | 7 | 14 | 48 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 3 | 1 | 3 | 2 | 12 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 3 | 2 | 4 | 2 | 5 | 3 | 2 | 23 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 19 | 22 | 36 | 52 | 57 | 70 | 78 | 342 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 2 | 1 | 2 | 3 | 15 |
| Bone and Connective Tissue | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 5 | 3 | 4 | 4 | 26 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 1 | 2 | 1 | 6 | 8 | 7 | 4 | 6 | 13 | 10 | 4 | 9 | 71 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 7 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 36 | 82 | 104 | 148 | 118 | 108 | 115 | 718 |
| Male Genital Organs | 0 | 2 | 7 | 4 | 6 | 4 | 7 | 1 | 5 | 3 | 1 | 0 | 3 | 2 | 0 | 45 |
| Kidney | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 6 | 4 | 9 | 9 | 6 | 9 | 16 | 11 | 74 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 6 | 14 | 10 | 12 | 16 | 24 | 88 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 4 |
| Brain & Central Nervous System | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 8 | 6 | 4 | 4 | 3 | 2 | 6 | 39 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 3 | 2 | 3 | 1 | 2 | 15 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Non-Hodgkin's Lymphoma | 1 | 0 | 2 | 1 | 3 | 2 | 3 | 6 | 7 | 10 | 15 | 12 | 12 | 8 | 29 | 111 |
| Hodgkin's Disease | 0 | 2 | 4 | 2 | 2 | 4 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 20 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 4 | 3 | 7 | 8 | 6 | 32 |
| Leukemia | 4 | 0 | 0 | 0 | 0 | 2 | 4 | 3 | 6 | 4 | 11 | 6 | 14 | 20 | 21 | 95 |
| Primary Unknown | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 6 | 2 | 6 | 7 | 11 | 13 | 9 | 57 |
| Other Primaries | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 8 | 5 | 11 | 11 | 6 | 14 | 59 |
| Total | 10 | 7 | 15 | 10 | 17 | 22 | 34 | 72 | 148 | 220 | 297 | 374 | 357 | 380 | 467 | 2430 |
| Non-Melanoma Skin | 0 | 0 | 1 | 0 | 5 | 10 | 19 | 43 | 81 | 114 | 119 | 179 | 212 | 246 | 497 | 1526 |
| Other: In Situ | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 9 | 10 | 20 | 21 | 30 | 50 | 49 | 81 | 274 |

INCIDENCE - AGE SPECIFIC NUMBERS (FEMALE) - 2007

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|----------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Oral Cavity | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 3 | 2 | 1 | 0 | 1 | 5 | 16 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 3 | 10 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 0 | 5 | 12 |
| Stomach | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 4 | 2 | 5 | 3 | 8 | 9 | 35 |
| Colon | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 3 | 15 | 10 | 16 | 29 | 23 | 25 | 95 | 222 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 6 | 5 | 6 | 7 | 14 | 16 | 12 | 26 | 95 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 7 | 12 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 1 | 2 | 0 | 2 | 7 | 3 | 9 | 29 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 1 | 3 | 5 | 7 | 9 | 12 | 37 | 80 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 3 | 1 | 2 | 3 | 3 | 5 | 23 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 0 | 0 | 6 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 11 | 15 | 27 | 53 | 39 | 46 | 62 | 65 | 323 |
| Respiratory System | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 8 |
| Bone and Connective Tissue | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 1 | 1 | 3 | 4 | 19 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 3 | 3 | 1 | 3 | 2 | 4 | 6 | 7 | 5 | 3 | 4 | 9 | 50 |
| Breast | 0 | 0 | 0 | 0 | 5 | 8 | 32 | 74 | 85 | 82 | 92 | 71 | 69 | 59 | 112 | 689 |
| Cervix: Invasive | 0 | 0 | 2 | 3 | 7 | 6 | 5 | 5 | 5 | 2 | 6 | 2 | 0 | 0 | 2 | 45 |
| Uterus | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 9 | 7 | 31 | 27 | 26 | 16 | 7 | 18 | 147 |
| Ovary | 0 | 0 | 1 | 1 | 3 | 1 | 4 | 6 | 8 | 13 | 6 | 7 | 6 | 10 | 18 | 84 |
| Female Genital Organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 4 | 4 | 4 | 8 | 25 |
| Kidney | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 4 | 5 | 6 | 4 | 7 | 9 | 14 | 56 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 2 | 5 | 6 | 4 | 7 | 10 | 38 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 4 | 2 | 10 |
| Brain & Central Nervous System | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 4 | 0 | 2 | 4 | 6 | 4 | 4 | 30 |
| Thyroid | 0 | 0 | 1 | 1 | 2 | 3 | 3 | 6 | 2 | 3 | 5 | 3 | 1 | 5 | 1 | 36 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Non-Hodgkin's Lymphoma | 1 | 0 | 1 | 0 | 0 | 2 | 6 | 6 | 5 | 12 | 10 | 6 | 9 | 17 | 24 | 99 |
| Hodgkin's Disease | 1 | 1 | 2 | 3 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 12 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 3 | 4 | 9 | 2 | 6 | 31 |
| Leukemia | 8 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 6 | 3 | 9 | 8 | 3 | 11 | 18 | 70 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 2 | 3 | 6 | 8 | 15 | 38 |
| Other Primaries | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 5 | 5 | 7 | 3 | 5 | 11 | 15 | 55 |
| Total | 14 | 3 | 10 | 16 | 22 | 35 | 85 | 152 | 186 | 232 | 283 | 263 | 265 | 294 | 548 | 2408 |
| Non-Melanoma Skin Cancer | 0 | 0 | 9 | 0 | 7 | 7 | 27 | 56 | 71 | 86 | 59 | 94 | 121 | 164 | 449 | 1150 |
| Cervix: In Situ | 0 | 1 | 43 | 49 | 45 | 15 | 17 | 7 | 3 | 2 | 1 | 0 | 0 | 0 | 1 | 184 |
| Other: In Situ | 0 | 1 | 0 | 1 | 3 | 2 | 17 | 15 | 23 | 30 | 29 | 27 | 37 | 38 | 110 | 333 |

INCIDENCE - AGE SPECIFIC NUMBERS (MALE) - 2007

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|----------|----------|-----------|-----------|-----------|-----------|-----------|------------|------------|------------|------------|------------|------------|------------|-------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 3 | 0 | 2 | 2 | 4 | 17 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 4 | 2 | 4 | 6 | 2 | 2 | 2 | 26 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 4 | 1 | 2 | 1 | 4 | 19 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 2 | 4 | 4 | 2 | 11 | 2 | 31 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 8 | 4 | 12 | 4 | 13 | 46 |
| Colon | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 6 | 8 | 22 | 25 | 32 | 42 | 33 | 55 | 228 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 15 | 21 | 20 | 24 | 27 | 18 | 29 | 158 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 4 | 4 | 3 | 2 | 3 | 23 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 2 | 4 | 5 | 5 | 22 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 11 | 7 | 8 | 17 | 9 | 9 | 70 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 3 | 4 | 5 | 1 | 5 | 4 | 27 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 5 | 4 | 9 | 4 | 2 | 28 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 8 | 12 | 31 | 51 | 50 | 65 | 63 | 78 | 361 |
| Respiratory System | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 4 | 5 | 4 | 20 |
| Bone and Connective Tissue | 2 | 1 | 0 | 0 | 0 | 2 | 3 | 1 | 1 | 1 | 1 | 0 | 2 | 4 | 9 | 27 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 2 | 1 | 1 | 2 | 5 | 10 | 6 | 5 | 9 | 9 | 5 | 8 | 63 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 18 | 54 | 81 | 134 | 165 | 186 | 124 | 104 | 870 |
| Male Genital Organs | 0 | 2 | 4 | 7 | 5 | 3 | 2 | 2 | 1 | 0 | 3 | 1 | 0 | 1 | 2 | 33 |
| Kidney | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 6 | 7 | 8 | 13 | 11 | 7 | 11 | 6 | 71 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 3 | 4 | 10 | 12 | 12 | 13 | 23 | 81 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 4 | 10 |
| Brain & Central Nervous System | 3 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 3 | 6 | 4 | 5 | 7 | 0 | 4 | 36 |
| Thyroid | 0 | 0 | 0 | 3 | 1 | 1 | 2 | 2 | 3 | 1 | 3 | 2 | 1 | 1 | 0 | 20 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Hodgkin's Lymphoma | 1 | 0 | 2 | 1 | 2 | 0 | 5 | 7 | 11 | 9 | 12 | 15 | 20 | 18 | 26 | 129 |
| Hodgkin's Disease | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 11 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 5 | 1 | 7 | 2 | 6 | 5 | 32 |
| Leukemia | 4 | 2 | 0 | 1 | 0 | 1 | 3 | 2 | 5 | 8 | 11 | 8 | 18 | 13 | 23 | 99 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 | 2 | 2 | 4 | 6 | 11 | 31 |
| Other Primaries | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 2 | 2 | 3 | 6 | 3 | 7 | 4 | 14 | 44 |
| Total | 11 | 6 | 9 | 16 | 14 | 17 | 34 | 81 | 166 | 247 | 351 | 387 | 470 | 372 | 454 | 2635 |
| Non-Melanoma Skin | 0 | 0 | 2 | 2 | 8 | 11 | 28 | 46 | 85 | 111 | 140 | 192 | 205 | 287 | 545 | 1662 |
| Other: In Situ | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 6 | 13 | 17 | 32 | 36 | 45 | 55 | 79 | 288 |

INCIDENCE - AGE SPECIFIC RATES PER 100,000 (FEMALE) - 2005

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-------------|-------------|-------------|-------------|-------------|--------------|--------------|--------------|--------------|--------------|---------------|---------------|---------------|---------------|---------------|--------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.3 | 0.2 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 10.7 | 9.3 | 16.1 | 5.6 | 12 | 9.9 | 2.9 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 3.2 | 0 | 2.6 | 2.9 | 3.6 | 4.6 | 10.7 | 0 | 6 | 0 | 1.6 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.1 | 0 | 0 | 5.6 | 6 | 13.2 | 1.6 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 6.3 | 5.1 | 0 | 5.9 | 3.6 | 0 | 5.4 | 16.8 | 18 | 36.3 | 4.9 |
| Colon | 0 | 0 | 2.6 | 3 | 6.5 | 3.2 | 2.6 | 10.3 | 17.6 | 50 | 102.2 | 161 | 129.1 | 197.6 | 260.5 | 42.3 |
| Rectum | 0 | 0 | 0 | 6.1 | 0 | 3.2 | 2.6 | 23.1 | 23.5 | 17.9 | 9.3 | 42.9 | 56.1 | 77.8 | 72.5 | 15.8 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.4 | 0 | 0 | 9.9 | 0.8 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 2.6 | 5.9 | 3.6 | 18.6 | 10.7 | 11.2 | 47.9 | 19.8 | 5.3 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 20.6 | 10.7 | 51.1 | 42.9 | 33.7 | 65.9 | 92.3 | 14.8 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 0 | 0 | 0 | 5.4 | 5.6 | 18 | 9.9 | 1.8 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.6 | 5.4 | 5.6 | 6 | 6.6 | 1.2 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 3.2 | 12.8 | 25.7 | 38.2 | 100.1 | 246.2 | 252.2 | 213.4 | 227.5 | 224.2 | 58.6 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 3.6 | 9.3 | 0 | 11.2 | 12 | 3.3 | 1.8 |
| Bone and Connective Tissue | 1 | 2.6 | 0 | 3 | 0 | 0 | 0 | 0 | 5.9 | 0 | 4.6 | 0 | 16.8 | 6 | 9.9 | 2.5 |
| Malignant Melanoma of Skin | 0 | 2.6 | 0 | 3 | 3.3 | 3.2 | 15.4 | 25.7 | 20.6 | 14.3 | 4.6 | 16.1 | 16.8 | 47.9 | 36.3 | 11.1 |
| Breast | 0 | 0 | 0 | 12.1 | 3.3 | 47.6 | 95 | 133.6 | 226.1 | 228.7 | 329.8 | 434.6 | 466 | 449 | 329.7 | 128.5 |
| Cervix: Invasive | 0 | 0 | 0 | 12.1 | 9.8 | 9.5 | 12.8 | 23.1 | 8.8 | 3.6 | 13.9 | 5.4 | 5.6 | 12 | 6.6 | 7.2 |
| Uterus | 0 | 0 | 0 | 3 | 6.5 | 6.3 | 12.8 | 20.6 | 55.8 | 60.7 | 92.9 | 42.9 | 44.9 | 53.9 | 62.6 | 23 |
| Ovary | 0 | 0 | 0 | 3 | 3.3 | 9.5 | 12.8 | 10.3 | 20.6 | 25 | 27.9 | 21.5 | 50.5 | 47.9 | 59.3 | 14.2 |
| Female Genital Organs | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 0 | 5.9 | 14.3 | 4.6 | 10.7 | 11.2 | 0 | 26.4 | 4.1 |
| Kidney | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 17.6 | 21.4 | 18.6 | 10.7 | 28.1 | 35.9 | 26.4 | 7.6 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.6 | 18.6 | 10.7 | 11.2 | 29.9 | 39.6 | 5.1 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.4 | 11.2 | 18 | 19.8 | 2.3 |
| Brain & Central Nervous System | 4.1 | 2.6 | 0 | 0 | 0 | 3.2 | 2.6 | 2.6 | 8.8 | 3.6 | 13.9 | 21.5 | 11.2 | 23.9 | 19.8 | 6 |
| Thyroid | 0 | 5.2 | 5.3 | 9.1 | 16.3 | 15.9 | 20.5 | 25.7 | 20.6 | 25 | 9.3 | 10.7 | 16.8 | 35.9 | 13.2 | 12.9 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 5.3 | 3 | 6.5 | 12.7 | 10.3 | 18 | 14.7 | 35.7 | 18.6 | 48.3 | 61.8 | 77.8 | 82.4 | 18.9 |
| Hodgkin's Disease | 0 | 2.6 | 5.3 | 6.1 | 9.8 | 3.2 | 0 | 0 | 2.9 | 0 | 0 | 0 | 0 | 18 | 3.3 | 2.7 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.9 | 17.9 | 23.2 | 10.7 | 5.6 | 12 | 19.8 | 4.5 |
| Leukemia | 5.2 | 0 | 2.6 | 0 | 0 | 9.5 | 2.6 | 5.1 | 5.9 | 17.9 | 18.6 | 21.5 | 67.4 | 59.9 | 52.7 | 12.7 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 2.9 | 3.6 | 18.6 | 16.1 | 22.5 | 47.9 | 92.3 | 9.7 |
| Other Primaries | 1 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 2.9 | 10.7 | 41.8 | 42.9 | 22.5 | 47.9 | 75.8 | 11.3 |
| Total | 12.4 | 15.5 | 21.1 | 63.6 | 65.2 | 139.5 | 223.4 | 344.2 | 540.2 | 696.8 | 1114.9 | 1287.8 | 1364.4 | 1718.2 | 1737.4 | 437.8 |

INCIDENCE - AGE SPECIFIC RATES PER 100,000 (MALE) - 2005

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|--------------|--------------|--------------|--------------|---------------|---------------|---------------|---------------|---------------|--------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.3 | 18.8 | 7.4 | 0 | 1.2 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 3.2 | 2.6 | 2.5 | 8.5 | 14 | 18.7 | 39.5 | 25 | 22.2 | 23.4 | 6.3 |
| Head and Neck | 0 | 0 | 0 | 2.9 | 6.4 | 0 | 0 | 0 | 22.6 | 7 | 0 | 22.6 | 18.8 | 22.2 | 29.3 | 5.5 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 5.7 | 7 | 18.7 | 11.3 | 31.3 | 44.4 | 58.5 | 6.3 |
| Stomach | 0 | 0 | 2.5 | 0 | 0 | 0 | 2.6 | 2.5 | 11.3 | 10.5 | 32.8 | 33.8 | 56.3 | 59.1 | 76.1 | 10.4 |
| Colon | 0 | 0 | 0 | 0 | 0 | 3.2 | 12.9 | 10.1 | 28.3 | 62.8 | 89 | 203 | 268.9 | 266.1 | 327.8 | 44.9 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 3.2 | 10.3 | 20.2 | 11.3 | 48.9 | 126.5 | 124 | 175.1 | 199.6 | 175.6 | 32.5 |
| Liver | 0 | 0 | 0 | 0 | 3.2 | 0 | 2.6 | 2.5 | 2.8 | 10.5 | 0 | 16.9 | 12.5 | 22.2 | 11.7 | 3.3 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 7 | 4.7 | 0 | 25 | 22.2 | 41 | 3.5 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 5 | 8.5 | 10.5 | 32.8 | 16.9 | 75 | 96.1 | 76.1 | 11.4 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 0 | 3.5 | 0 | 0 | 12.5 | 7.4 | 23.4 | 1.8 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.5 | 3.5 | 9.4 | 22.6 | 56.3 | 14.8 | 11.7 | 4.5 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 20.2 | 31.1 | 48.9 | 187.4 | 315.7 | 512.7 | 569.2 | 491.7 | 73.5 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 2.5 | 0 | 3.5 | 4.7 | 22.6 | 6.3 | 14.8 | 11.7 | 2.6 |
| Bone and Connective Tissue | 1 | 4.9 | 5 | 0 | 0 | 3.2 | 2.6 | 2.5 | 0 | 0 | 9.4 | 11.3 | 6.3 | 0 | 17.6 | 3.2 |
| Malignant Melanoma of Skin | 0 | 0 | 2.5 | 0 | 6.4 | 9.5 | 15.4 | 15.1 | 28.3 | 41.9 | 51.5 | 28.2 | 43.8 | 66.5 | 64.4 | 16.4 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 0 | 0 | 0 | 0 | 22.2 | 5.9 | 1 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 22.7 | 110.3 | 296.7 | 618.5 | 947.2 | 862.8 | 983.2 | 872.3 | 168.2 |
| Male Genital Organs | 0 | 2.4 | 15 | 8.7 | 6.4 | 9.5 | 10.3 | 0 | 0 | 0 | 4.7 | 11.3 | 6.3 | 0 | 11.7 | 4.9 |
| Kidney | 3 | 0 | 0 | 0 | 3.2 | 6.3 | 12.9 | 12.6 | 17 | 17.5 | 60.9 | 78.9 | 50 | 88.7 | 52.7 | 16.4 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 10.1 | 14.1 | 17.5 | 37.5 | 73.3 | 56.3 | 133.1 | 169.8 | 18.1 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18.8 | 0 | 5.9 | 0.8 |
| Brain & Central Nervous System | 6.9 | 2.4 | 2.5 | 2.9 | 0 | 0 | 12.9 | 7.6 | 2.8 | 7 | 23.4 | 5.6 | 12.5 | 29.6 | 17.6 | 7.1 |
| Thyroid | 0 | 0 | 0 | 0 | 6.4 | 0 | 2.6 | 2.5 | 2.8 | 7 | 9.4 | 5.6 | 0 | 7.4 | 5.9 | 2.4 |
| Other Endocrine Glands | 1 | 0 | 0 | 0 | 0 | 3.2 | 0 | 0 | 0 | 3.5 | 0 | 0 | 12.5 | 0 | 0 | 1 |
| Non-Hodgkin's Lymphoma | 0 | 2.4 | 0 | 0 | 3.2 | 6.3 | 12.9 | 17.7 | 19.8 | 24.4 | 42.2 | 56.4 | 75 | 162.6 | 93.7 | 19.5 |
| Hodgkin's Disease | 0 | 7.3 | 7.5 | 2.9 | 6.4 | 0 | 5.1 | 2.5 | 0 | 3.5 | 4.7 | 0 | 0 | 0 | 0 | 2.8 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 8.5 | 17.5 | 46.9 | 22.6 | 31.3 | 22.2 | 29.3 | 7.1 |
| Leukemia | 4.9 | 7.3 | 2.5 | 2.9 | 6.4 | 0 | 12.9 | 5 | 11.3 | 20.9 | 32.8 | 67.7 | 81.3 | 103.5 | 117.1 | 18.7 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.6 | 8.5 | 3.5 | 23.4 | 45.1 | 62.5 | 66.5 | 105.4 | 11.2 |
| Other Primaries | 0 | 0 | 2.5 | 0 | 0 | 3.2 | 2.6 | 2.5 | 8.5 | 10.5 | 37.5 | 62 | 81.3 | 118.3 | 134.6 | 16 |
| Total | 16.8 | 26.9 | 40.1 | 20.3 | 47.8 | 50.7 | 141.4 | 176.7 | 376.3 | 708.7 | 1527.4 | 2255.2 | 2694.8 | 3171.4 | 3061.7 | 522.5 |

INCIDENCE - AGE SPECIFIC RATES PER 100,000 (FEMALE) - 2006

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|-------|--------|--------|--------|----------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.3 | 5.7 | 6 | 6.6 | 1 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 9.9 | 0 | 5.2 | 11.5 | 3.5 | 4.6 | 15.8 | 11.5 | 24.1 | 23.1 | 5.3 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 3.3 | 0 | 0 | 5.7 | 0 | 0 | 15.8 | 5.7 | 12.1 | 6.6 | 2.2 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.9 | 9.2 | 15.8 | 11.5 | 6 | 16.5 | 3 |
| Stomach | 0 | 0 | 2.7 | 0 | 0 | 0 | 0 | 7.8 | 2.9 | 3.5 | 0 | 21.1 | 51.5 | 30.1 | 33 | 6.7 |
| Colon | 0 | 0 | 0 | 0 | 0 | 3.3 | 8.1 | 10.4 | 17.2 | 34.6 | 96.5 | 110.9 | 91.6 | 259.3 | 250.6 | 39.7 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 13.2 | 8.1 | 15.6 | 28.6 | 38 | 36.8 | 42.2 | 74.5 | 102.5 | 33 | 17.8 |
| Liver | 1.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.9 | 0 | 0 | 5.3 | 11.5 | 12.1 | 6.6 | 1.8 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 5.7 | 0 | 18.4 | 21.1 | 11.5 | 12.1 | 33 | 4.9 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 5.7 | 17.3 | 32.2 | 31.7 | 40.1 | 54.3 | 69.2 | 11.5 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 0 | 2.9 | 3.5 | 0 | 5.3 | 5.7 | 6 | 13.2 | 2 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.2 | 0 | 0 | 6 | 6.6 | 1 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 3.3 | 16.1 | 15.6 | 45.8 | 96.8 | 193 | 374.8 | 252 | 307.5 | 250.6 | 67.4 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 6.9 | 0 | 5.3 | 0 | 6 | 6.6 | 1.4 |
| Bone and Connective Tissue | 4.3 | 2.6 | 0 | 9.3 | 6.7 | 0 | 0 | 0 | 8.6 | 10.4 | 4.6 | 5.3 | 0 | 6 | 0 | 3.8 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 3.1 | 0 | 9.9 | 10.8 | 15.6 | 11.5 | 24.2 | 9.2 | 21.1 | 34.4 | 18.1 | 23.1 | 9.3 |
| Breast | 0 | 0 | 2.7 | 3.1 | 43.5 | 29.6 | 83.4 | 137.6 | 203.4 | 311.2 | 399.7 | 390.6 | 435.3 | 373.9 | 359.4 | 133.8 |
| Cervix: Invasive | 0 | 0 | 0 | 3.1 | 20.1 | 16.5 | 10.8 | 15.6 | 14.3 | 3.5 | 4.6 | 5.3 | 5.7 | 6 | 9.9 | 6.9 |
| Uterus | 0 | 0 | 0 | 3.1 | 0 | 0 | 5.4 | 15.6 | 40.1 | 72.6 | 59.7 | 100.3 | 74.5 | 96.5 | 49.5 | 23.7 |
| Ovary | 0 | 0 | 2.7 | 6.2 | 3.3 | 6.6 | 0 | 20.8 | 22.9 | 17.3 | 23 | 58.1 | 45.8 | 66.3 | 56.1 | 15.6 |
| Female Genital Organs | 0 | 0 | 0 | 0 | 0 | 6.6 | 2.7 | 0 | 0 | 3.5 | 4.6 | 0 | 11.5 | 12.1 | 26.4 | 3.4 |
| Kidney | 1.1 | 0 | 0 | 0 | 0 | 6.6 | 5.4 | 7.8 | 8.6 | 31.1 | 23 | 31.7 | 45.8 | 42.2 | 39.6 | 11.5 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 0 | 0 | 10.4 | 9.2 | 15.8 | 28.6 | 12.1 | 9.9 | 3.8 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.8 | 5.7 | 18.1 | 6.6 | 1.8 |
| Brain & Central Nervous System | 1.1 | 2.6 | 2.7 | 0 | 3.3 | 13.2 | 2.7 | 5.2 | 8.6 | 10.4 | 36.8 | 0 | 17.2 | 18.1 | 16.5 | 7.1 |
| Thyroid | 0 | 2.6 | 2.7 | 12.4 | 16.7 | 3.3 | 16.1 | 31.2 | 22.9 | 13.8 | 27.6 | 5.3 | 5.7 | 6 | 6.6 | 10.5 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.5 | 0 | 0 | 0 | 0 | 0 | 0.2 |
| Non-Hodgkin's Lymphoma | 1.1 | 0 | 0 | 0 | 13.4 | 3.3 | 10.8 | 10.4 | 17.2 | 20.7 | 41.4 | 63.3 | 97.4 | 102.5 | 92.3 | 21.5 |
| Hodgkin's Disease | 2.1 | 5.3 | 5.4 | 0 | 0 | 0 | 5.4 | 0 | 2.9 | 0 | 4.6 | 10.6 | 0 | 6 | 0 | 2.6 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 3.3 | 0 | 0 | 2.9 | 6.9 | 13.8 | 15.8 | 34.4 | 12.1 | 23.1 | 4.9 |
| Leukemia | 3.2 | 7.9 | 0 | 0 | 6.7 | 3.3 | 5.4 | 7.8 | 14.3 | 24.2 | 23 | 31.7 | 68.7 | 48.2 | 59.4 | 14.8 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 3.3 | 5.4 | 2.6 | 8.6 | 3.5 | 27.6 | 31.7 | 34.4 | 24.1 | 98.9 | 11.9 |
| Other Primaries | 2.1 | 0 | 0 | 0 | 0 | 6.6 | 2.7 | 0 | 8.6 | 10.4 | 18.4 | 21.1 | 34.4 | 36.2 | 56.1 | 9.5 |
| Total | 16 | 21.1 | 19 | 40.4 | 113.9 | 144.9 | 204.5 | 332.3 | 524.2 | 788.4 | 1130.3 | 1494 | 1552.1 | 1748.7 | 1688.3 | 462.2 |

INCIDENCE - AGE SPECIFIC RATES PER 100,000 (MALE) - 2006

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-------------|-------------|-----------|-----------|-------------|-------------|-------------|--------------|--------------|--------------|---------------|---------------|---------------|---------------|---------------|--------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.2 | 16.8 | 6.3 | 0 | 17.5 | 1.8 |
| Oral Cavity | 0 | 0 | 0 | 0 | 3.3 | 3.3 | 0 | 5.1 | 13.9 | 23.8 | 18.4 | 28 | 6.3 | 7.4 | 0 | 5.4 |
| Head and Neck | 1 | 0 | 0 | 0 | 0 | 3.3 | 2.7 | 2.6 | 5.5 | 17 | 23 | 16.8 | 25.3 | 29.5 | 11.7 | 5.8 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 8.3 | 10.2 | 9.2 | 0 | 44.3 | 29.5 | 52.5 | 6 |
| Stomach | 0 | 2.5 | 0 | 0 | 0 | 0 | 0 | 2.6 | 5.5 | 13.6 | 27.6 | 78.5 | 19 | 66.4 | 64.2 | 10.3 |
| Colon | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 10.2 | 36 | 47.5 | 73.5 | 179.3 | 221.6 | 346.6 | 314.9 | 43.6 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 25.6 | 27.7 | 44.1 | 78.1 | 100.9 | 114 | 118 | 175 | 26.7 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 10.2 | 27.6 | 11.2 | 12.7 | 14.8 | 17.5 | 3.8 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 3.3 | 0 | 2.6 | 0 | 3.4 | 4.6 | 11.2 | 6.3 | 22.1 | 17.5 | 2.6 |
| Pancreas | 0 | 0 | 0 | 0 | 3.3 | 3.3 | 2.7 | 5.1 | 5.5 | 10.2 | 32.2 | 33.6 | 25.3 | 51.6 | 81.6 | 9.7 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 6.8 | 0 | 16.8 | 6.3 | 22.1 | 11.7 | 2.4 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 3.3 | 2.7 | 0 | 8.3 | 6.8 | 18.4 | 11.2 | 31.7 | 22.1 | 11.7 | 4.6 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20.5 | 52.7 | 74.7 | 165.4 | 291.4 | 361 | 516.3 | 454.9 | 68.8 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 3.4 | 23 | 11.2 | 6.3 | 14.8 | 17.5 | 3 |
| Bone and Connective Tissue | 2 | 2.5 | 0 | 0 | 3.3 | 3.3 | 2.7 | 5.1 | 2.8 | 0 | 4.6 | 28 | 19 | 29.5 | 23.3 | 5.2 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 3 | 6.6 | 3.3 | 16.4 | 20.5 | 19.4 | 13.6 | 27.6 | 72.9 | 63.3 | 29.5 | 52.5 | 14.3 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 0 | 9.2 | 5.6 | 6.3 | 7.4 | 5.8 | 1.4 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 5.5 | 12.8 | 99.8 | 278.3 | 477.9 | 829.5 | 747.3 | 796.5 | 670.7 | 144.4 |
| Male Genital Organs | 0 | 5 | 18.2 | 12 | 19.9 | 13.3 | 19.2 | 2.6 | 13.9 | 10.2 | 4.6 | 0 | 19 | 14.8 | 0 | 9 |
| Kidney | 0 | 2.5 | 0 | 0 | 0 | 0 | 8.2 | 15.4 | 11.1 | 30.5 | 41.4 | 33.6 | 57 | 118 | 75.8 | 15.3 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.7 | 8.3 | 20.4 | 64.3 | 56 | 76 | 118 | 140 | 17.7 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.6 | 11.2 | 0 | 0 | 5.8 | 0.8 |
| Brain & Central Nervous System | 2 | 0 | 0 | 0 | 3.3 | 3.3 | 2.7 | 2.6 | 22.2 | 20.4 | 18.4 | 22.4 | 19 | 14.8 | 35 | 7.8 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 6.6 | 2.7 | 2.6 | 0 | 0 | 13.8 | 11.2 | 19 | 7.4 | 11.7 | 3 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 3.4 | 0 | 0 | 0 | 0 | 0 | 0.4 |
| Non-Hodgkin's Lymphoma | 1 | 0 | 5.2 | 3 | 10 | 6.6 | 8.2 | 15.4 | 19.4 | 33.9 | 68.9 | 67.3 | 76 | 59 | 169.1 | 22.3 |
| Hodgkin's Disease | 0 | 5 | 10.4 | 6 | 6.6 | 13.3 | 2.7 | 2.6 | 0 | 6.8 | 0 | 0 | 0 | 7.4 | 5.8 | 4 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 10.2 | 18.4 | 16.8 | 44.3 | 59 | 35 | 6.4 |
| Leukemia | 4.1 | 0 | 0 | 0 | 0 | 6.6 | 11 | 7.7 | 16.6 | 13.6 | 50.5 | 33.6 | 88.7 | 147.5 | 122.5 | 19.1 |
| Primary Unknown | 0 | 0 | 2.6 | 0 | 0 | 0 | 2.7 | 2.6 | 16.6 | 6.8 | 27.6 | 39.2 | 69.7 | 95.9 | 58.3 | 11.7 |
| Other Primaries | 0 | 0 | 2.6 | 0 | 0 | 0 | 0 | 0 | 8.3 | 27.1 | 23 | 61.6 | 69.7 | 44.3 | 93.3 | 12.3 |
| Total | 10.2 | 17.6 | 39 | 30 | 56.5 | 73.1 | 93.1 | 184.3 | 410.3 | 746.6 | 1364.7 | 2096.1 | 2260.8 | 2809.9 | 2752.7 | 489.8 |

INCIDENCE - AGE SPECIFIC RATES PER 100,000 (FEMALE) - 2007

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|--------|--------|--------|--------|----------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.6 | 0.4 |
| Oral Cavity | 0 | 0 | 0 | 3 | 0 | 3.3 | 0 | 5.1 | 0 | 10.2 | 8.6 | 5.2 | 0 | 6.1 | 16.4 | 3.1 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 2.6 | 0 | 0 | 4.3 | 5.2 | 5.8 | 12.1 | 9.8 | 2 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.4 | 8.6 | 10.4 | 11.6 | 0 | 16.4 | 2.4 |
| Stomach | 0 | 0 | 0 | 3 | 0 | 3.3 | 2.8 | 0 | 2.7 | 13.6 | 8.6 | 26.1 | 17.4 | 48.6 | 29.5 | 6.9 |
| Colon | 0 | 0 | 0 | 0 | 0 | 6.6 | 11.2 | 7.7 | 41.2 | 34 | 68.5 | 151.4 | 133.3 | 151.8 | 311.6 | 43.5 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 3.3 | 5.6 | 18 | 13.7 | 20.4 | 29.9 | 73.1 | 92.8 | 72.9 | 85.3 | 18.8 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.3 | 5.2 | 17.4 | 0 | 23 | 2.4 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 3.3 | 0 | 0 | 10.3 | 2.7 | 6.8 | 0 | 10.4 | 40.6 | 18.2 | 29.5 | 5.7 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 3.3 | 5.6 | 7.7 | 2.7 | 10.2 | 21.4 | 36.5 | 52.2 | 72.9 | 121.4 | 15.7 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 5.1 | 8.2 | 10.2 | 4.3 | 10.4 | 17.4 | 18.2 | 16.4 | 4.5 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.8 | 5.2 | 11.6 | 0 | 0 | 1.2 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 28.2 | 38.5 | 91.8 | 226.8 | 203.6 | 266.7 | 376.5 | 216.5 | 63.3 |
| Respiratory System | 0 | 0 | 2.7 | 3 | 0 | 0 | 8.4 | 0 | 0 | 6.8 | 0 | 0 | 0 | 6.1 | 0 | 1.6 |
| Bone and Connective Tissue | 2.1 | 2.6 | 2.7 | 0 | 0 | 0 | 0 | 2.6 | 5.5 | 6.8 | 4.3 | 5.2 | 5.8 | 18.2 | 13.1 | 3.7 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 9.1 | 9.8 | 3.3 | 8.4 | 5.1 | 11 | 20.4 | 29.9 | 26.1 | 17.4 | 24.3 | 29.5 | 9.8 |
| Breast | 0 | 0 | 0 | 0 | 16.3 | 26.3 | 89.6 | 190 | 233.6 | 278.7 | 393.6 | 370.7 | 400 | 358.3 | 370.7 | 135.2 |
| Cervix: Invasive | 0 | 0 | 5.3 | 9.1 | 22.8 | 19.7 | 14 | 12.8 | 13.7 | 6.8 | 25.7 | 10.4 | 0 | 0 | 6.6 | 8.8 |
| Uterus | 0 | 0 | 0 | 0 | 0 | 9.9 | 8.4 | 23.1 | 19.2 | 105.4 | 115.5 | 135.7 | 92.8 | 42.5 | 59 | 28.8 |
| Ovary | 0 | 0 | 2.7 | 3 | 9.8 | 3.3 | 11.2 | 15.4 | 22 | 44.2 | 25.7 | 36.5 | 34.8 | 60.7 | 59 | 16.5 |
| Female Genital Organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 5.5 | 3.4 | 4.3 | 20.9 | 23.2 | 24.3 | 26.2 | 4.9 |
| Kidney | 1.1 | 0 | 0 | 0 | 0 | 3.3 | 2.8 | 10.3 | 11 | 17 | 25.7 | 20.9 | 40.6 | 54.7 | 45.9 | 11 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 8.4 | 0 | 2.7 | 6.8 | 21.4 | 31.3 | 23.2 | 42.5 | 32.8 | 7.4 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.4 | 0 | 10.4 | 5.8 | 24.3 | 6.6 | 2 |
| Brain & Central Nervous System | 1.1 | 0 | 2.7 | 3 | 0 | 0 | 2.8 | 5.1 | 11 | 0 | 8.6 | 20.9 | 34.8 | 24.3 | 13.1 | 5.9 |
| Thyroid | 0 | 0 | 2.7 | 3 | 6.5 | 9.9 | 8.4 | 15.4 | 5.5 | 10.2 | 21.4 | 10.4 | 5.8 | 30.4 | 3.3 | 6.9 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 |
| Non-Hodgkin's Lymphoma | 1.1 | 0 | 2.7 | 0 | 0 | 6.6 | 16.8 | 15.4 | 13.7 | 40.8 | 42.8 | 31.3 | 52.2 | 103.2 | 78.7 | 19.4 |
| Hodgkin's Disease | 1.1 | 2.6 | 5.3 | 9.1 | 3.3 | 6.6 | 2.8 | 0 | 0 | 0 | 4.3 | 0 | 0 | 0 | 0 | 2.4 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 2.6 | 8.2 | 6.8 | 12.8 | 20.9 | 52.2 | 12.1 | 19.7 | 6.1 |
| Leukemia | 8.5 | 2.6 | 0 | 0 | 0 | 3.3 | 0 | 5.1 | 16.5 | 10.2 | 38.5 | 41.8 | 17.4 | 66.8 | 59 | 13.7 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 0 | 5.5 | 3.4 | 8.6 | 15.7 | 34.8 | 48.6 | 49.2 | 7.4 |
| Other Primaries | 0 | 0 | 0 | 3 | 0 | 3.3 | 2.8 | 2.6 | 13.7 | 17 | 34.2 | 15.7 | 29 | 66.8 | 49.2 | 11 |
| Total | 14.9 | 7.9 | 26.7 | 48.3 | 71.6 | 115.1 | 238.1 | 392.8 | 508.5 | 788.6 | 1215.1 | 1367.8 | 1536.3 | 1785.5 | 1804.2 | 472.1 |

INCIDENCE - AGE SPECIFIC RATES PER 100,000 (MALE) - 2007

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-------------|-----------|-----------|-----------|-----------|-------------|-------------|--------------|--------------|--------------|---------------|---------------|---------------|---------------|---------------|------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 8 | 6.6 | 12.7 | 0 | 12.8 | 14.8 | 22.8 | 3.4 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 6.5 | 2.8 | 2.5 | 10.7 | 6.6 | 17 | 33 | 12.8 | 14.8 | 11.4 | 5.2 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.3 | 16.5 | 17 | 5.5 | 12.8 | 7.4 | 22.8 | 3.8 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 2.5 | 10.7 | 6.6 | 17 | 22 | 12.8 | 81.5 | 11.4 | 6.1 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 13.2 | 34 | 22 | 76.7 | 29.6 | 74.3 | 9.1 |
| Colon | 0 | 2.5 | 0 | 0 | 3.2 | 3.3 | 5.6 | 15.3 | 21.4 | 72.8 | 106.2 | 175.8 | 268.6 | 244.4 | 319.9 | 45.4 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.2 | 40.1 | 69.4 | 85 | 131.9 | 172.7 | 133.3 | 165.7 | 31.3 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 5.3 | 13.2 | 17 | 22 | 19.2 | 14.8 | 17.1 | 4.6 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 6.6 | 12.7 | 11 | 25.6 | 37 | 28.6 | 4.4 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 3.3 | 5.6 | 5.1 | 10.7 | 36.4 | 29.7 | 44 | 108.7 | 66.6 | 51.4 | 13.9 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 5.6 | 7.6 | 0 | 9.9 | 17 | 27.5 | 6.4 | 37 | 22.8 | 5.4 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 5.3 | 3.3 | 21.2 | 22 | 57.6 | 29.6 | 11.4 | 5.6 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 2.9 | 0 | 0 | 8.5 | 20.4 | 34.7 | 102.5 | 216.7 | 274.7 | 422 | 473.9 | 462.7 | 73 |
| Respiratory System | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 2.7 | 6.6 | 8.5 | 5.5 | 25.6 | 37 | 22.8 | 4.2 |
| Bone and Connective Tissue | 2 | 2.5 | 0 | 0 | 0 | 6.5 | 8.5 | 2.5 | 2.7 | 3.3 | 4.2 | 0 | 12.8 | 29.6 | 51.4 | 5.4 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 5.7 | 3.2 | 3.3 | 5.6 | 12.7 | 26.7 | 19.8 | 21.2 | 49.4 | 57.6 | 37 | 45.7 | 12.5 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.5 | 0 | 0 | 5.7 | 0.4 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 11.3 | 45.8 | 144.3 | 267.9 | 569.2 | 912 | 1189.4 | 918.2 | 594.1 | 172.7 |
| Male Genital Organs | 0 | 5 | 10.2 | 20.1 | 16.1 | 9.8 | 5.6 | 5.1 | 2.7 | 0 | 12.7 | 5.5 | 0 | 7.4 | 11.4 | 6.5 |
| Kidney | 0 | 0 | 0 | 0 | 3.2 | 3.3 | 0 | 15.3 | 18.7 | 26.5 | 55.2 | 60.4 | 44.8 | 81.5 | 34.3 | 14.1 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 3.3 | 0 | 7.6 | 8 | 13.2 | 42.5 | 65.9 | 76.7 | 96.3 | 131.4 | 16.1 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.2 | 5.5 | 12.8 | 14.8 | 22.8 | 2 |
| Brain & Central Nervous System | 3.1 | 0 | 0 | 2.9 | 0 | 0 | 5.6 | 2.5 | 8 | 19.8 | 17 | 27.5 | 44.8 | 0 | 22.8 | 7.1 |
| Thyroid | 0 | 0 | 0 | 8.6 | 3.2 | 3.3 | 5.6 | 5.1 | 8 | 3.3 | 12.7 | 16.5 | 6.4 | 7.4 | 0 | 4.2 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Hodgkin's Lymphoma | 1 | 0 | 5.1 | 2.9 | 6.4 | 0 | 14.1 | 17.8 | 29.4 | 29.8 | 51 | 87.9 | 127.9 | 133.3 | 148.5 | 25.8 |
| Hodgkin's Disease | 0 | 0 | 5.1 | 0 | 6.4 | 6.5 | 0 | 0 | 5.3 | 3.3 | 4.2 | 0 | 6.4 | 0 | 0 | 2.2 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 2.5 | 10.7 | 16.5 | 4.2 | 38.5 | 12.8 | 44.4 | 28.6 | 6.3 |
| Leukemia | 4.1 | 5 | 0 | 2.9 | 0 | 3.3 | 8.5 | 5.1 | 13.4 | 26.5 | 46.7 | 44 | 115.1 | 96.3 | 131.4 | 19.6 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 2.7 | 9.9 | 8.5 | 11 | 25.6 | 44.4 | 62.8 | 6.1 |
| Other Primaries | 0 | 0 | 2.6 | 0 | 3.2 | 3.3 | 0 | 5.1 | 5.3 | 9.9 | 25.5 | 16.5 | 44.8 | 29.6 | 80 | 8.7 |
| Total | 11.2 | 15 | 23 | 46 | 45 | 55.7 | 98.9 | 206.1 | 446.4 | 820.1 | 1491.1 | 2142.6 | 3011.9 | 2762.1 | 2616.2 | 525 |

MORTALITY - AGE SPECIFIC NUMBERS (FEMALE) - 2005

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|----------|----------|----------|----------|----------|-----------|-----------|-----------|-----------|-----------|-----------|------------|------------|------------|-------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 5 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 3 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 3 | 8 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 3 | 1 | 3 | 10 | 21 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 7 | 4 | 5 | 11 | 16 | 46 | 94 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 3 | 3 | 3 | 4 | 6 | 23 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 5 | 6 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 0 | 6 | 3 | 14 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 7 | 5 | 7 | 16 | 27 | 67 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 | 6 | 12 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 7 | 14 | 15 | 34 | 33 | 37 | 42 | 69 | 253 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 3 |
| Bone and Connective Tissue | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 7 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 2 | 7 |
| Breast | 0 | 0 | 0 | 0 | 1 | 1 | 6 | 9 | 13 | 12 | 14 | 15 | 18 | 11 | 68 | 168 |
| Cervix: Invasive | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 1 | 1 | 1 | 1 | 0 | 0 | 3 | 12 |
| Uterus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 2 | 2 | 2 | 0 | 11 | 21 |
| Ovary | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 8 | 5 | 2 | 4 | 9 | 8 | 10 | 49 |
| Female Genital Organs | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 2 | 1 | 4 | 12 |
| Kidney | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 4 | 3 | 8 | 19 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 8 | 14 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 4 |
| Brain & Central Nervous System | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 3 | 0 | 3 | 3 | 1 | 4 | 6 | 25 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Other Endocrine Glands | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 3 | 7 | 9 | 19 | 46 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 2 | 3 | 8 | 17 |
| Leukemia | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 4 | 1 | 4 | 3 | 2 | 6 | 5 | 23 | 53 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 6 | 4 | 6 | 4 | 13 | 35 | 71 |
| Other Primaries | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 2 | 6 | 13 |
| Total | 3 | 1 | 5 | 3 | 1 | 3 | 20 | 33 | 58 | 63 | 86 | 95 | 127 | 158 | 396 | 1052 |

MORTALITY - AGE SPECIFIC NUMBERS (MALE) - 2005

| SITE | Age Group | | | | | | | | | | | | | | All Ages | |
|--------------------------------|-----------|----------|----------|----------|----------|----------|-----------|-----------|-----------|-----------|-----------|------------|------------|------------|------------|-------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | | 80+ |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 8 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 1 | 2 | 7 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 3 | 3 | 2 | 2 | 4 | 18 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 7 | 1 | 8 | 8 | 11 | 41 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 9 | 4 | 11 | 14 | 13 | 34 | 91 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 5 | 2 | 8 | 4 | 7 | 14 | 46 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 2 | 2 | 4 | 3 | 1 | 18 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 4 | 2 | 4 | 16 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 1 | 6 | 4 | 10 | 14 | 13 | 53 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 5 | 10 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 5 | 0 | 2 | 13 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 13 | 22 | 26 | 49 | 62 | 56 | 77 | 310 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bone and Connective Tissue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 4 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 2 | 0 | 3 | 2 | 1 | 6 | 17 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 3 | 0 | 7 | 8 | 24 | 34 | 110 | 191 |
| Male Genital Organs | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Kidney | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 2 | 4 | 4 | 10 | 27 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 7 | 3 | 12 | 18 | 46 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 |
| Brain & Central Nervous System | 2 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 1 | 3 | 5 | 1 | 0 | 5 | 5 | 26 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 4 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 6 | 3 | 5 | 5 | 11 | 16 | 49 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 1 | 3 | 2 | 1 | 1 | 5 | 17 |
| Leukemia | 2 | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 2 | 3 | 6 | 5 | 7 | 6 | 25 | 62 |
| Primary Unknown | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 3 | 6 | 8 | 11 | 13 | 13 | 31 | 89 |
| Other Primaries | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 5 | 3 | 10 |
| Total | 4 | 1 | 2 | 3 | 1 | 4 | 13 | 30 | 38 | 76 | 98 | 130 | 177 | 205 | 400 | 1182 |

MORTALITY - AGE SPECIFIC NUMBERS (FEMALE) - 2006

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|----------|----------|----------|----------|----------|-----------|-----------|-----------|-----------|-----------|------------|------------|------------|------------|-------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | | | | | | | | | | | | | | | | |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 4 | 8 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 4 | 2 | 3 | 5 | 18 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 5 | 4 | 6 | 18 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 7 | 5 | 5 | 8 | 13 | 51 | 94 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 3 | 1 | 5 | 1 | 8 | 20 |
| Liver | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 3 | 2 | 3 | 5 | 17 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 12 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 6 | 4 | 9 | 8 | 10 | 24 | 68 |
| Digestive Tract | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 3 | 3 | 12 | 21 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 5 | 12 | 18 | 30 | 37 | 33 | 27 | 65 | 230 |
| Respiratory System | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 3 |
| Bone and Connective Tissue | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 1 | 7 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 5 |
| Breast | 0 | 0 | 0 | 0 | 1 | 0 | 5 | 8 | 16 | 12 | 9 | 23 | 18 | 20 | 45 | 157 |
| Cervix: Invasive | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 2 | 11 |
| Uterus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 3 | 7 | 1 | 4 | 19 |
| Ovary | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 5 | 7 | 6 | 9 | 12 | 19 | 63 |
| Female Genital Organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 6 | 11 |
| Kidney | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 1 | 0 | 2 | 3 | 14 | 26 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 2 | 5 | 12 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 4 |
| Brain & Central Nervous System | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 4 | 5 | 2 | 3 | 1 | 6 | 27 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 6 | 11 | 5 | 19 | 47 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 2 | 3 | 4 | 4 | 19 |
| Leukemia | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 2 | 1 | 4 | 6 | 24 | 41 |
| Primary Unknown | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 2 | 4 | 2 | 8 | 10 | 7 | 12 | 41 | 91 |
| Other Primaries | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 7 | 10 |
| Total | 1 | 1 | 2 | 1 | 2 | 4 | 20 | 32 | 57 | 69 | 90 | 120 | 143 | 141 | 385 | 1068 |

MORTALITY - AGE SPECIFIC NUMBERS (MALE) - 2006

| SITE | Age Group | | | | | | | | | | | | | | All Ages | |
|--------------------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|----------|------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | | 80+ |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 1 | 2 | 3 | 10 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 1 | 2 | 1 | 3 | 1 | 13 |
| Esophagus | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 2 | 3 | 7 | 6 | 12 | 37 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 1 | 2 | 4 | 8 | 19 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 6 | 4 | 4 | 16 | 10 | 20 | 33 | 95 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 6 | 6 | 4 | 8 | 6 | 34 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 4 | 2 | 2 | 4 | 3 | 19 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 4 |
| Pancreas | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 4 | 5 | 5 | 8 | 11 | 20 | 56 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 3 | 4 | 2 | 4 | 9 | 26 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 3 | 3 | 2 | 2 | 16 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 15 | 11 | 38 | 37 | 57 | 58 | 83 | 305 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 5 |
| Bone and Connective Tissue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 2 | 5 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 4 | 2 | 0 | 2 | 0 | 4 | 15 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 10 | 9 | 12 | 41 | 126 | 203 |
| Male Genital Organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 3 |
| Kidney | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 2 | 7 | 5 | 13 | 36 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 | 8 | 8 | 21 | 43 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Brain & Central Nervous System | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 2 | 4 | 1 | 2 | 3 | 19 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 2 | 1 | 8 | 6 | 5 | 5 | 18 | 49 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 4 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 4 | 3 | 2 | 7 | 19 |
| Leukemia | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 2 | 2 | 0 | 3 | 4 | 9 | 22 | 46 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 7 | 3 | 6 | 13 | 12 | 14 | 33 | 92 |
| Other Primaries | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 6 | 10 | 20 |
| Total | 0 | 0 | 2 | 2 | 4 | 2 | 11 | 19 | 55 | 51 | 106 | 129 | 157 | 216 | 444 | 1198 |

MORTALITY - AGE SPECIFIC NUMBERS (FEMALE) - 2007

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|----------|----------|----------|----------|----------|-----------|-----------|-----------|-----------|-----------|------------|------------|------------|------------|-------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 1 | 6 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 3 | 1 | 6 | 13 |
| Stomach | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 11 | 17 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 7 | 8 | 7 | 12 | 14 | 48 | 98 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 3 | 1 | 4 | 4 | 15 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 9 | 14 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 2 | 3 | 2 | 6 | 17 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 3 | 6 | 5 | 7 | 6 | 39 | 71 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 4 | 1 | 1 | 3 | 3 | 14 | 28 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 4 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 8 | 17 | 29 | 32 | 41 | 55 | 65 | 252 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Bone and Connective Tissue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 2 | 2 | 7 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 12 |
| Breast | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 10 | 8 | 10 | 14 | 9 | 20 | 23 | 64 | 163 |
| Cervix: Invasive | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 1 | 3 | 1 | 0 | 1 | 1 | 1 | 13 |
| Uterus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 3 | 4 | 1 | 2 | 9 | 24 |
| Ovary | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 4 | 5 | 6 | 7 | 8 | 8 | 22 | 63 |
| Female Genital Organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 4 |
| Kidney | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 2 | 3 | 12 | 25 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 2 | 11 | 18 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Brain & Central Nervous System | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 5 | 1 | 4 | 5 | 3 | 23 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 3 |
| Other Endocrine Glands | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 6 | 2 | 1 | 5 | 4 | 12 | 32 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 3 | 3 | 9 | 19 |
| Leukemia | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 5 | 1 | 4 | 18 | 33 |
| Primary Unknown | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 1 | 6 | 5 | 15 | 17 | 31 | 81 |
| Other Primaries | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 7 |
| Total | 2 | 0 | 2 | 1 | 2 | 9 | 11 | 31 | 38 | 68 | 93 | 100 | 139 | 166 | 408 | 1070 |

MORTALITY - AGE SPECIFIC NUMBERS (MALE) - 2007

| SITE | Age Group | | | | | | | | | | | | | | All Ages | |
|--------------------------------|-----------|----------|----------|----------|----------|----------|----------|-----------|-----------|-----------|------------|------------|------------|------------|-------------|-------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | | 80+ |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 5 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 3 | 4 | 3 | 1 | 3 | 18 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 5 | 5 | 6 | 4 | 9 | 7 | 41 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 3 | 4 | 5 | 7 | 7 | 30 |
| Colon | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 4 | 5 | 12 | 15 | 14 | 18 | 35 | 107 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 4 | 4 | 6 | 10 | 32 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 1 | 5 | 3 | 3 | 19 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 3 | 2 | 12 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 5 | 7 | 6 | 5 | 12 | 6 | 9 | 56 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 3 | 5 | 8 | 23 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 2 | 6 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 11 | 22 | 29 | 32 | 59 | 49 | 83 | 292 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 3 |
| Bone and Connective Tissue | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 2 | 1 | 9 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 1 | 2 | 2 | 1 | 2 | 2 | 14 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 5 | 4 | 15 | 36 | 133 | 196 |
| Male Genital Organs | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Kidney | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 3 | 1 | 6 | 4 | 5 | 26 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 5 | 6 | 24 | 43 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| Brain & Central Nervous System | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 3 | 4 | 5 | 1 | 5 | 3 | 4 | 29 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 3 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 5 | 9 | 7 | 23 | 50 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 4 | 8 | 1 | 6 | 25 |
| Leukemia | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 4 | 7 | 10 | 18 | 48 |
| Primary Unknown | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 4 | 5 | 12 | 12 | 22 | 31 | 94 |
| Other Primaries | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 8 | 13 |
| Total | 2 | 2 | 2 | 2 | 2 | 4 | 8 | 25 | 42 | 76 | 103 | 115 | 189 | 202 | 431 | 1205 |

MORTALITY - AGE SPECIFIC RATES PER 100,000 (FEMALE) - 2005

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|------------|------------|-------------|------------|------------|------------|-------------|-------------|--------------|--------------|--------------|--------------|--------------|--------------|---------------|--------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.6 | 6 | 9.9 | 1 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.2 | 6 | 0 | 0.6 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.4 | 11.2 | 12 | 9.9 | 1.6 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 3.2 | 0 | 0 | 2.9 | 7.1 | 0 | 16.1 | 5.6 | 18 | 33 | 4.1 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.7 | 25 | 18.6 | 26.8 | 61.8 | 95.8 | 151.7 | 18.3 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 5.9 | 3.6 | 13.9 | 16.1 | 16.8 | 23.9 | 19.8 | 4.5 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.6 | 0 | 0 | 0 | 0 | 16.5 | 1.2 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 0 | 0 | 9.3 | 5.4 | 0 | 35.9 | 9.9 | 2.7 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 5.9 | 7.1 | 32.5 | 26.8 | 39.3 | 95.8 | 89 | 13 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.6 | 4.6 | 0 | 5.6 | 18 | 19.8 | 2.3 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.7 | 0 | 0 | 0 | 0.4 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 18 | 41.1 | 53.6 | 157.9 | 177.1 | 207.7 | 251.4 | 227.5 | 49.3 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.9 | 0 | 0 | 5.4 | 0 | 0 | 3.3 | 0.6 |
| Bone and Connective Tissue | 1 | 0 | 2.6 | 0 | 0 | 0 | 2.6 | 2.6 | 0 | 0 | 0 | 0 | 5.6 | 0 | 6.6 | 1.4 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 2.9 | 0 | 0 | 0 | 11.2 | 6 | 6.6 | 1.4 |
| Breast | 0 | 0 | 0 | 0 | 3.3 | 3.2 | 15.4 | 23.1 | 38.2 | 42.9 | 65 | 80.5 | 101.1 | 65.9 | 224.2 | 32.7 |
| Cervix: Invasive | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 10.3 | 2.9 | 3.6 | 4.6 | 5.4 | 0 | 0 | 9.9 | 2.3 |
| Uterus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 10.7 | 9.3 | 10.7 | 11.2 | 0 | 36.3 | 4.1 |
| Ovary | 0 | 0 | 2.6 | 0 | 0 | 0 | 2.6 | 2.6 | 23.5 | 17.9 | 9.3 | 21.5 | 50.5 | 47.9 | 33 | 9.5 |
| Female Genital Organs | 0 | 0 | 0 | 3 | 0 | 0 | 2.6 | 0 | 2.9 | 0 | 4.6 | 5.4 | 11.2 | 6 | 13.2 | 2.3 |
| Kidney | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 9.3 | 5.4 | 22.5 | 18 | 26.4 | 3.7 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.6 | 5.4 | 11.2 | 12 | 26.4 | 2.7 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 6.6 | 0.8 |
| Brain & Central Nervous System | 0 | 2.6 | 5.3 | 0 | 0 | 3.2 | 2.6 | 0 | 8.8 | 0 | 13.9 | 16.1 | 5.6 | 23.9 | 19.8 | 4.9 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.3 | 0.2 |
| Other Endocrine Glands | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 5.1 | 5.9 | 3.6 | 9.3 | 16.1 | 39.3 | 53.9 | 62.6 | 9 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.3 | 0.2 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.9 | 7.1 | 0 | 5.4 | 11.2 | 18 | 26.4 | 3.3 |
| Leukemia | 0 | 0 | 2.6 | 3 | 0 | 0 | 7.7 | 10.3 | 2.9 | 14.3 | 13.9 | 10.7 | 33.7 | 29.9 | 75.8 | 10.3 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 0 | 2.9 | 21.4 | 18.6 | 32.2 | 22.5 | 77.8 | 115.4 | 13.8 |
| Other Primaries | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.9 | 0 | 0 | 5.4 | 11.2 | 12 | 19.8 | 2.5 |
| Total | 3.1 | 2.6 | 13.2 | 9.1 | 3.3 | 9.5 | 51.4 | 84.8 | 170.3 | 225.1 | 399.5 | 509.7 | 713.1 | 945.9 | 1305.6 | 204.9 |

MORTALITY - AGE SPECIFIC RATES PER 100,000 (MALE) - 2005

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|------------|------------|----------|------------|------------|-------------|-------------|-------------|--------------|--------------|--------------|--------------|---------------|---------------|---------------|--------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 5 | 0 | 3.5 | 4.7 | 0 | 6.3 | 14.8 | 0 | 1.6 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 0 | 0 | 0 | 11.3 | 6.3 | 7.4 | 11.7 | 1.4 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 0 | 10.5 | 14.1 | 16.9 | 12.5 | 14.8 | 23.4 | 3.5 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 5.7 | 10.5 | 32.8 | 5.6 | 50 | 59.1 | 64.4 | 8.1 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 7.6 | 5.7 | 31.4 | 18.7 | 62 | 87.5 | 96.1 | 199 | 17.9 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 7.7 | 2.5 | 5.7 | 17.5 | 9.4 | 45.1 | 25 | 51.7 | 82 | 9.1 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.7 | 14 | 9.4 | 11.3 | 25 | 22.2 | 5.9 | 3.5 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 9.4 | 11.3 | 25 | 14.8 | 23.4 | 3.2 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.6 | 5.7 | 3.5 | 28.1 | 22.6 | 62.5 | 103.5 | 76.1 | 10.4 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.3 | 6.3 | 14.8 | 29.3 | 2 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 0 | 3.5 | 14.1 | 5.6 | 31.3 | 0 | 11.7 | 2.6 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.6 | 36.8 | 76.8 | 121.8 | 276.3 | 387.6 | 414 | 450.8 | 61.1 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bone and Connective Tissue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 0 | 0 | 0 | 0 | 14.8 | 5.9 | 0.8 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.6 | 0 | 7 | 0 | 16.9 | 12.5 | 7.4 | 35.1 | 3.3 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 10.1 | 8.5 | 0 | 32.8 | 45.1 | 150.1 | 251.3 | 644 | 37.6 |
| Male Genital Organs | 0 | 0 | 2.5 | 2.9 | 0 | 0 | 0 | 2.5 | 0 | 0 | 0 | 0 | 0 | 0 | 5.9 | 0.8 |
| Kidney | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 2.8 | 3.5 | 18.7 | 11.3 | 25 | 29.6 | 58.5 | 5.3 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.5 | 14.1 | 39.5 | 18.8 | 88.7 | 105.4 | 9.1 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.6 | 6.3 | 0 | 5.9 | 0.6 |
| Brain & Central Nervous System | 2 | 0 | 0 | 2.9 | 0 | 6.3 | 0 | 2.5 | 2.8 | 10.5 | 23.4 | 5.6 | 0 | 37 | 29.3 | 5.1 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 3.2 | 0 | 2.5 | 0 | 0 | 4.7 | 0 | 6.3 | 0 | 0 | 0.8 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 5.7 | 20.9 | 14.1 | 28.2 | 31.3 | 81.3 | 93.7 | 9.7 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.4 | 5.9 | 0.4 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 3.2 | 2.6 | 0 | 5.7 | 3.5 | 14.1 | 11.3 | 6.3 | 7.4 | 29.3 | 3.3 |
| Leukemia | 2 | 2.4 | 2.5 | 0 | 3.2 | 0 | 5.1 | 2.5 | 5.7 | 10.5 | 28.1 | 28.2 | 43.8 | 44.4 | 146.4 | 12.2 |
| Primary Unknown | 0 | 0 | 0 | 2.9 | 0 | 0 | 5.1 | 2.5 | 8.5 | 20.9 | 37.5 | 62 | 81.3 | 96.1 | 181.5 | 17.5 |
| Other Primaries | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.4 | 0 | 0 | 37 | 17.6 | 2 |
| Total | 3.9 | 2.4 | 5 | 8.7 | 3.2 | 12.7 | 33.4 | 75.7 | 107.5 | 265.3 | 459.2 | 732.9 | 1106.7 | 1515.5 | 2341.6 | 232.9 |

MORTALITY - AGE SPECIFIC RATES PER 100,000 (FEMALE) - 2006

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|----------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.6 | 0 | 5.7 | 12.1 | 13.2 | 1.6 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 0 | 2.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0.4 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 3.5 | 9.2 | 21.1 | 11.5 | 18.1 | 16.5 | 3.6 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 2.9 | 0 | 0 | 5.3 | 28.6 | 24.1 | 19.8 | 3.6 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 7.8 | 2.9 | 24.2 | 23 | 26.4 | 45.8 | 78.4 | 168.2 | 18.6 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 2.9 | 0 | 13.8 | 5.3 | 28.6 | 6 | 26.4 | 4 |
| Liver | 1.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.9 | 6.9 | 0 | 15.8 | 11.5 | 18.1 | 16.5 | 3.4 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 0 | 0 | 3.5 | 9.2 | 10.6 | 11.5 | 12.1 | 6.6 | 2.4 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.2 | 14.3 | 20.7 | 18.4 | 47.5 | 45.8 | 60.3 | 79.1 | 13.4 |
| Digestive Tract | 0 | 0 | 0 | 0 | 3.3 | 0 | 0 | 2.6 | 2.9 | 0 | 0 | 0 | 17.2 | 18.1 | 39.6 | 4.2 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.7 | 0 | 0 | 0.2 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 3.3 | 5.4 | 13 | 34.4 | 62.2 | 137.8 | 195.3 | 189 | 162.8 | 214.3 | 45.5 |
| Respiratory System | 0 | 0 | 2.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.6 | 0 | 0 | 0 | 3.3 | 0.6 |
| Bone and Connective Tissue | 0 | 2.6 | 0 | 0 | 0 | 0 | 0 | 2.6 | 2.9 | 3.5 | 0 | 0 | 11.5 | 0 | 3.3 | 1.4 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 3.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.1 | 6.6 | 1 |
| Breast | 0 | 0 | 0 | 0 | 3.3 | 0 | 13.5 | 20.8 | 45.8 | 41.5 | 41.4 | 121.4 | 103.1 | 120.6 | 148.4 | 31 |
| Cervix: Invasive | 0 | 0 | 0 | 0 | 0 | 3.3 | 8.1 | 0 | 2.9 | 3.5 | 4.6 | 10.6 | 0 | 0 | 6.6 | 2.2 |
| Uterus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 5.7 | 0 | 4.6 | 15.8 | 40.1 | 6 | 13.2 | 3.8 |
| Ovary | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.2 | 8.6 | 17.3 | 32.2 | 31.7 | 51.5 | 72.4 | 62.7 | 12.5 |
| Female Genital Organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.2 | 10.6 | 5.7 | 0 | 19.8 | 2.2 |
| Kidney | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 0 | 5.7 | 10.4 | 4.6 | 0 | 11.5 | 18.1 | 46.2 | 5.1 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.3 | 22.9 | 12.1 | 16.5 | 2.4 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.7 | 12.1 | 3.3 | 0.8 |
| Brain & Central Nervous System | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 7.8 | 5.7 | 13.8 | 23 | 10.6 | 17.2 | 6 | 19.8 | 5.3 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 3.3 | 0.6 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 3.3 | 0.4 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.7 | 10.4 | 4.6 | 31.7 | 63 | 30.1 | 62.7 | 9.3 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0.2 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 2.9 | 3.5 | 13.8 | 10.6 | 17.2 | 24.1 | 13.2 | 3.8 |
| Leukemia | 0 | 0 | 0 | 3.1 | 0 | 0 | 2.7 | 0 | 0 | 6.9 | 9.2 | 5.3 | 22.9 | 36.2 | 79.1 | 8.1 |
| Primary Unknown | 0 | 0 | 2.7 | 0 | 0 | 3.3 | 8.1 | 5.2 | 11.5 | 6.9 | 36.8 | 52.8 | 40.1 | 72.4 | 135.2 | 18 |
| Other Primaries | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.2 | 0 | 5.7 | 0 | 23.1 | 2 |
| Total | 1.1 | 2.6 | 5.4 | 3.1 | 6.7 | 13.2 | 53.8 | 83.1 | 163.3 | 238.6 | 413.5 | 633.5 | 819 | 850.2 | 1269.5 | 211.1 |

MORTALITY - AGE SPECIFIC RATES PER 100,000 (MALE) - 2006

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|----------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 0 | 0 | 6.8 | 0 | 5.6 | 6.3 | 14.8 | 17.5 | 2 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 6.8 | 4.6 | 11.2 | 6.3 | 22.1 | 5.8 | 2.6 |
| Esophagus | 0 | 0 | 2.6 | 0 | 0 | 0 | 5.5 | 2.6 | 5.5 | 3.4 | 9.2 | 16.8 | 44.3 | 44.3 | 70 | 7.4 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 0 | 13.8 | 5.6 | 12.7 | 29.5 | 46.7 | 3.8 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 | 5.5 | 0 | 16.6 | 13.6 | 18.4 | 89.7 | 63.3 | 147.5 | 192.5 | 19.1 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 2.8 | 6.8 | 27.6 | 33.6 | 25.3 | 59 | 35 | 6.8 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 8.3 | 0 | 18.4 | 11.2 | 12.7 | 29.5 | 17.5 | 3.8 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.6 | 0 | 6.3 | 7.4 | 5.8 | 0.8 |
| Pancreas | 0 | 0 | 0 | 0 | 3.3 | 0 | 2.7 | 2.6 | 0 | 13.6 | 23 | 28 | 50.7 | 81.1 | 116.6 | 11.3 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 2.6 | 5.5 | 0 | 13.8 | 22.4 | 12.7 | 29.5 | 52.5 | 5.2 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.5 | 10.2 | 4.6 | 16.8 | 19 | 14.8 | 11.7 | 3.2 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.4 | 41.6 | 37.3 | 174.6 | 207.4 | 361 | 427.8 | 484 | 61.3 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 0 | 0 | 5.6 | 6.3 | 0 | 11.7 | 1 |
| Bone and Connective Tissue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 3.4 | 0 | 0 | 6.3 | 0 | 11.7 | 1 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 0 | 5.5 | 0 | 2.8 | 13.6 | 9.2 | 0 | 12.7 | 0 | 23.3 | 3 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.8 | 0.2 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.5 | 10.2 | 45.9 | 50.4 | 76 | 302.4 | 734.8 | 40.8 |
| Male Genital Organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 0 | 4.6 | 5.6 | 0 | 0 | 0 | 0.6 |
| Kidney | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 5.5 | 6.8 | 18.4 | 11.2 | 44.3 | 36.9 | 75.8 | 7.2 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.8 | 4.6 | 16.8 | 50.7 | 59 | 122.5 | 8.6 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Brain & Central Nervous System | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 2.6 | 8.3 | 6.8 | 9.2 | 22.4 | 6.3 | 14.8 | 17.5 | 3.8 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.6 | 6.3 | 0 | 0 | 0.4 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.4 | 0 | 0 | 6.3 | 0 | 0 | 0.4 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 6.6 | 0 | 0 | 5.1 | 5.5 | 3.4 | 36.8 | 33.6 | 31.7 | 36.9 | 105 | 9.9 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.2 | 0 | 7.4 | 5.8 | 0.8 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 0 | 9.2 | 22.4 | 19 | 14.8 | 40.8 | 3.8 |
| Leukemia | 0 | 0 | 2.6 | 6 | 3.3 | 0 | 0 | 0 | 5.5 | 6.8 | 0 | 16.8 | 25.3 | 66.4 | 128.3 | 9.2 |
| Primary Unknown | 0 | 0 | 0 | 0 | 0 | 6.6 | 2.7 | 2.6 | 19.4 | 10.2 | 27.6 | 72.9 | 76 | 103.3 | 192.5 | 18.5 |
| Other Primaries | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.4 | 9.2 | 0 | 6.3 | 44.3 | 58.3 | 4 |
| Total | 0 | 0 | 5.2 | 6 | 13.3 | 6.6 | 30.1 | 48.6 | 152.5 | 173.1 | 487.1 | 723 | 994.2 | 1593 | 2589.4 | 240.9 |

MORTALITY - AGE SPECIFIC RATES PER 100,000 (FEMALE) - 2007

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|------------|----------|------------|----------|------------|-------------|-------------|-------------|--------------|--------------|--------------|--------------|--------------|---------------|---------------|--------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.4 | 4.3 | 10.4 | 5.8 | 0 | 3.3 | 1.2 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.1 | 0 | 0.4 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.8 | 0 | 5.2 | 17.4 | 6.1 | 19.7 | 2.5 |
| Stomach | 0 | 0 | 2.7 | 0 | 0 | 3.3 | 0 | 0 | 0 | 3.4 | 0 | 0 | 17.4 | 0 | 36.1 | 3.3 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 0 | 23.8 | 34.2 | 36.5 | 69.6 | 85 | 157.5 | 19.2 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 3.3 | 0 | 0 | 2.7 | 3.4 | 0 | 15.7 | 5.8 | 24.3 | 13.1 | 2.9 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.4 | 5.8 | 12.1 | 29.5 | 2.7 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.2 | 0 | 4.3 | 10.4 | 17.4 | 12.1 | 19.7 | 3.3 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 0 | 5.6 | 2.6 | 5.5 | 10.2 | 25.7 | 26.1 | 40.6 | 36.4 | 127.9 | 13.9 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 0 | 13.6 | 4.3 | 5.2 | 17.4 | 18.2 | 45.9 | 5.5 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.4 | 0 | 5.2 | 5.8 | 0 | 3.3 | 0.8 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.8 | 22 | 57.8 | 124.1 | 167.1 | 237.7 | 334 | 213.2 | 49.4 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 0 | 0 | 0 | 0 | 0 | 3.3 | 0.4 |
| Bone and Connective Tissue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.5 | 3.4 | 0 | 0 | 0 | 12.1 | 6.6 | 1.4 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 2.7 | 6.8 | 8.6 | 5.2 | 5.8 | 12.1 | 3.3 | 2.4 |
| Breast | 0 | 0 | 0 | 0 | 3.3 | 6.6 | 5.6 | 25.7 | 22 | 34 | 59.9 | 47 | 115.9 | 139.7 | 209.9 | 31.9 |
| Cervix: Invasive | 0 | 0 | 2.7 | 0 | 0 | 0 | 8.4 | 2.6 | 2.7 | 10.2 | 4.3 | 0 | 5.8 | 6.1 | 3.3 | 2.5 |
| Uterus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.1 | 5.5 | 3.4 | 12.8 | 20.9 | 5.8 | 12.1 | 29.5 | 4.7 |
| Ovary | 0 | 0 | 0 | 0 | 0 | 3.3 | 0 | 5.1 | 11 | 17 | 25.7 | 36.5 | 46.4 | 48.6 | 72.2 | 12.3 |
| Female Genital Organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 0 | 0 | 0 | 5.8 | 0 | 6.6 | 0.8 |
| Kidney | 1.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.4 | 4.3 | 26.1 | 11.6 | 18.2 | 39.4 | 4.9 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6 | 0 | 0 | 4.3 | 10.4 | 5.8 | 12.1 | 36.1 | 3.5 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.3 | 0.2 |
| Brain & Central Nervous System | 1.1 | 0 | 0 | 0 | 0 | 6.6 | 2.8 | 0 | 2.7 | 0 | 21.4 | 5.2 | 23.2 | 30.4 | 9.8 | 4.5 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.4 | 0 | 0 | 3.3 | 0.6 |
| Other Endocrine Glands | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 2.6 | 0 | 20.4 | 8.6 | 5.2 | 29 | 24.3 | 39.4 | 6.3 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.1 | 3.3 | 0.4 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 0 | 4.3 | 10.4 | 17.4 | 18.2 | 29.5 | 3.7 |
| Leukemia | 0 | 0 | 0 | 0 | 0 | 3.3 | 2.8 | 0 | 0 | 3.4 | 8.6 | 26.1 | 5.8 | 24.3 | 59 | 6.5 |
| Primary Unknown | 0 | 0 | 0 | 0 | 3.3 | 0 | 2.8 | 5.1 | 5.5 | 3.4 | 25.7 | 26.1 | 87 | 103.2 | 101.7 | 15.9 |
| Other Primaries | 0 | 0 | 0 | 0 | 0 | 3.3 | 0 | 0 | 0 | 0 | 12.8 | 0 | 0 | 0 | 9.8 | 1.4 |
| Total | 2.1 | 0 | 5.3 | 3 | 6.5 | 29.6 | 30.8 | 79.6 | 104.4 | 231.1 | 397.9 | 522.1 | 805.8 | 1008.1 | 1338.4 | 209.6 |

MORTALITY - AGE SPECIFIC RATES PER 100,000 (MALE) - 2007

| SITE | Age Group | | | | | | | | | | | | | | | All Ages |
|--------------------------------|-----------|----------|------------|------------|------------|-------------|-------------|-------------|--------------|--------------|--------------|--------------|---------------|---------------|-------------|------------|
| | 0-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80+ | |
| Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.7 | 0.2 |
| Oral Cavity | 0 | 0 | 0 | 0 | 0 | 3.3 | 0 | 2.5 | 0 | 0 | 8.5 | 0 | 6.4 | 0 | 0 | 1 |
| Head and Neck | 0 | 0 | 0 | 0 | 0 | 3.3 | 0 | 0 | 2.7 | 6.6 | 12.7 | 22 | 19.2 | 7.4 | 17.1 | 3.6 |
| Esophagus | 0 | 0 | 0 | 0 | 0 | 3.3 | 0 | 5.1 | 5.3 | 16.5 | 21.2 | 33 | 25.6 | 66.6 | 40 | 8.1 |
| Stomach | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 5.3 | 3.3 | 12.7 | 22 | 32 | 51.8 | 40 | 5.9 |
| Colon | 0 | 0 | 0 | 0 | 3.2 | 0 | 2.8 | 5.1 | 10.7 | 16.5 | 51 | 82.4 | 89.5 | 133.3 | 199.9 | 21.2 |
| Rectum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 2.7 | 6.6 | 17 | 22 | 25.6 | 44.4 | 57.1 | 6.3 |
| Liver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 9.9 | 12.7 | 5.5 | 32 | 22.2 | 17.1 | 3.8 |
| Gall Bladder and Biliary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.3 | 4.2 | 16.5 | 12.8 | 22.2 | 11.4 | 2.4 |
| Pancreas | 0 | 0 | 0 | 0 | 0 | 3.3 | 5.6 | 7.6 | 13.4 | 23.1 | 25.5 | 27.5 | 76.7 | 44.4 | 51.4 | 11.1 |
| Digestive Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.3 | 6.6 | 4.2 | 11 | 19.2 | 37 | 45.7 | 4.6 |
| Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.7 | 0 | 0 | 0 | 19.2 | 0 | 11.4 | 1.2 |
| Trachea, Bronchus, and Lung | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 15.3 | 29.4 | 72.8 | 123.2 | 175.8 | 377.3 | 362.9 | 474.1 | 57.9 |
| Respiratory System | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.3 | 4.2 | 0 | 0 | 0 | 5.7 | 0.6 |
| Bone and Connective Tissue | 0 | 2.5 | 2.6 | 0 | 0 | 0 | 0 | 2.5 | 0 | 0 | 0 | 0 | 19.2 | 14.8 | 5.7 | 1.8 |
| Malignant Melanoma of Skin | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 7.6 | 0 | 3.3 | 8.5 | 11 | 6.4 | 14.8 | 11.4 | 2.8 |
| Breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.5 | 0 | 0 | 5.7 | 0.4 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.3 | 3.3 | 21.2 | 22 | 95.9 | 266.6 | 759.7 | 38.9 |
| Male Genital Organs | 0 | 2.5 | 0 | 2.9 | 0 | 0 | 2.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.7 | 0.8 |
| Kidney | 0 | 0 | 0 | 0 | 0 | 0 | 2.8 | 2.5 | 2.7 | 13.2 | 12.7 | 5.5 | 38.4 | 29.6 | 28.6 | 5.2 |
| Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 22 | 32 | 44.4 | 137.1 | 8.5 |
| Other Urinary Tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.4 | 7.4 | 5.7 | 0.6 |
| Brain & Central Nervous System | 0 | 0 | 0 | 2.9 | 3.2 | 0 | 0 | 5.1 | 8 | 13.2 | 21.2 | 5.5 | 32 | 22.2 | 22.8 | 5.8 |
| Thyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.2 | 0 | 6.4 | 0 | 5.7 | 0.6 |
| Other Endocrine Glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Hodgkin's Lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.3 | 9.9 | 4.2 | 27.5 | 57.6 | 51.8 | 131.4 | 9.9 |
| Hodgkin's Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.7 | 0.2 |
| Multiple Myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.9 | 12.7 | 22 | 51.2 | 7.4 | 34.3 | 5 |
| Leukemia | 1 | 0 | 2.6 | 0 | 0 | 0 | 0 | 0 | 0 | 13.2 | 12.7 | 22 | 44.8 | 74.1 | 102.8 | 9.5 |
| Primary Unknown | 1 | 0 | 0 | 0 | 0 | 0 | 2.8 | 5.1 | 10.7 | 13.2 | 21.2 | 65.9 | 76.7 | 162.9 | 177.1 | 18.6 |
| Other Primaries | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.3 | 4.2 | 5.5 | 6.4 | 7.4 | 45.7 | 2.6 |
| Total | 2 | 5 | 5.1 | 5.7 | 6.4 | 13.1 | 22.6 | 63.6 | 112.3 | 251.3 | 437.6 | 631.8 | 1208.6 | 1495.9 | 2462 | 239 |

Contact Information

For more information about the report or to request additional copies, contact the Saskatchewan Cancer Agency Department of Epidemiology through the Contact Us link on the Agency's website at www.saskcancer.ca. Electronic copies are also available through the website.

Saskatchewan Cancer Agency

#204-3775 Pasqua Street
Regina, Saskatchewan S4S 6W8
306-585-1831
www.saskcancer.ca